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Abstract 
Acute Respiratory Infection in Pre-School Children 
Katie Rose 
Introduction: Acute respiratory infection (ARI) is a major cause of morbidity and mortality 
worldwide, being responsible for 3.5 million deaths annually. Despite this the precise 
aetiology of ARI is often unclear, and the pathogenesis remains poorly understood. The aims 
of this study were i) to investigate the viral and atypical bacterial causes of ARI in a clinically 
and demographically well defined population of children less than five years of age and ii) to 
investigate host immunological response to ARI caused by different pathogens and in 
different severities of disease. 
Methods: Clinical and demographic data, along with nasopharyngeal aspirate samples were 
collected from 407 pre-school children who presented with ARI to the IMIP Children’s 
Hospital, Recife, Brazil over a 12 month period. Multiplex PCR was used to detect 17 different 
respiratory pathogens.  
The concentrations of nine cytokines were determined in a selection of samples from 
children with ARI caused by different pathogens and in differing severities of human 
respiratory syncytial virus (hRSV) disease.  
Results: At least one pathogen was detected in 85.5% of samples. The pathogens detected 
most frequently were hRSV (in 37.3% of samples), adenovirus (AdV; 24.8%), human 
rhinovirus (hRV; 18.9%), human bocavirus (hBoV; 18.7%), human metapneumovirus (hMPV; 
10.3%) and Mycoplasma pneumoniae (Mpp; 9.8%). Co-infection with multiple pathogens was 
detected in 39.6% of samples, with the pathogens most frequently detected in co-infection 
being AdV (in 52.8% of co-infections), hRSV (44.1%), hBoV (41.6%) and hRV (26.7%). Infection 
with Mpp or hRSV was associated with hospital admission and more severe disease.  
Cytokine profiles were similar in ARI caused by different pathogens and in different severities 
of disease.  
Conclusions:  We have described high rates of pathogen detection and co-infection, with 
particularly high rates of Mpp, AdV and hBoV infection. Our results may reflect the type of 
samples collected, the number of pathogens tested for, and/or the population demographics. 
The high prevalence of Mpp is more commonly associated with ARI in older children, and our 
findings may have implications for antibiotic use in this age group. 
Differing pathogens and differing severities of disease were not associated with particular 
patterns of cytokine production in the upper respiratory tract. This may reflect the type of 
sample or the particular cytokines investigated.  
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1 Introduction 
1.1 Acute Respiratory Infection 
1.1.1 Definition 
Acute respiratory infection (ARI) describes a multitude of signs and symptoms, essentially 
including all types of infection of the respiratory tract. It is characterised by cough or 
wheeze, with or without the presence of fever, acute rhinitis, otitis media and pharyngitis1. 
1.1.2 Burden 
The World Health Organisation (WHO) estimates that respiratory infections account for 6% 
of the total global burden of disease – a higher percentage than diarrhoeal disease, cancer, 
human immunodeficiency virus (HIV) infection, ischaemic heart disease or malaria2. ARI is 
the third most common cause of death worldwide, and the most important in developing 
countries3 4. Worldwide, ARI is responsible for 3.5 million deaths each year, and just under 
two million of these are children under the age of five5. 
Pneumonia is the most common cause of death in children under the age of five, causing an 
estimated 19-21% of all deaths in this age group6. 
The WHO has calculated the burden of disease associated with ARI using disability adjusted 
life years (DALYs), which incorporate both loss of life in terms of deaths due to disease 
(mortality) and loss of ‘healthy’ life (i.e. disability) due to disease (morbidity), it was found 
that ARI caused the loss of 2,983 DALYs per 100,000 population in the world’s poorest 
regions, in comparison to loss of 137 DALYs per 100,000 population in the world’s richest 
regions2. 
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In developed countries, ARI are the largest contributor to the total infectious disease 
burden. In the United States of America (USA) it has been estimated that ARI cause 
between 545,000 and 840,000 admissions in under 18 year olds each year, accounting for 
between 14 and 20% of all admissions in this age group7. Statistics show that for the 
majority of health problems, advancement in management or prevention is decreasing the 
burden of particular diseases. However, in ARI there has been very little change in the 
number of DALYs lost per 100,000 population between 1990 and 20022. Firstly, this may be 
explained by the ageing population seen in so many developed countries. Along with young 
children, the elderly are more likely to develop an ARI in the first place, and more likely 
once they have an ARI to develop a severe infection requiring hospitalisation8. Secondly 
new respiratory pathogens, or strains of already known pathogens, are emerging 
frequently, which can be increasingly virulent causing widespread problems worldwide, or 
increasingly severe and more difficult to manage2. 
1.1.3 Epidemiology 
Age groups 
Acute respiratory infections affect all age groups, although the very young and the elderly 
are most likely to suffer severe disease and require hospital admission8. 
Seasonal Distribution 
ARI occur throughout the year, however most studies find more infections occur in the 
autumn and winter months9-11. In paediatric studies, there is a strong peak incidence in the 
winter months, particularly in children under one year of age. This is due to the large 
number of infections caused by human respiratory syncytial virus (hRSV), the most common 
ARI causing pathogen in this age group. hRSV has a strong seasonality, peaking in the winter 
months in temperate climates, and in the wetter months in tropical climates10, with very 
few infections being detected in the summer months. Peaks are seen in other pathogens, 
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however, none have such a distinct seasonality as hRSV infection, and patterns of particular 
pathogens tend to vary from year to year. Human metapneumovirus (hMPV) for example, 
has been found to peak in some years at the same time as hRSV infection12, while other 
years it may peak immediately after the hRSV peak, or months later13 14. Other pathogens 
such as human rhinovirus (hRV) and adenovirus (AdV) are prevalent throughout the     
year10 15. 
1.1.4 Risk Factors 
Risk factors for ARI can be split into clinical and demographic factors. Clinical risk factors 
include male sex; prematurity; low birth weight; co-existing cardiac or respiratory 
problems; immunodeficiency and birth during the first half of the hRSV season. 
Demographic risk factors include a lack of breastfeeding; multiple siblings/crowded living 
conditions; a low socioeconomic status and smokers in the household16. 
Breastfeeding 
Many studies have found associations between breast-feeding and protection against ARI, 
specifically against ARI hospitalisation, and with a greater effect in developing countries17-19. 
Breast-feeding is beneficial due to colostrum containing hRSV-IgA and lactoferrin, both of 
which have antiviral properties, and it is also thought to promote lung maturation, having a 
particularly positive effect in the very young, and premature infants16. 
Overcrowding 
Many studies have found associations between crowded living conditions and an increased 
risk of ARI. Increasing numbers of people sharing a bedroom with the child; increased 
numbers of children under the age of 12 in the household and living with school-age 
siblings, have all been shown to be independent risk factors20-23. 
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Socio-economic status 
Low socioeconomic status has itself been found to be an independent risk factor for 
bronchiolitis, with one study finding children in the most deprived area of one particular 
city in Sweden to be almost twice as likely to need hospitalisation for bronchiolitis than 
those in the rest of the city24. Explanations for low socioeconomic status leading to 
increased risk of ARI are probably due to previously mentioned risk factors, including an 
increased likelihood of over-crowding, and parental smoking, as several studies have found 
increased rates of smokers in lower socioeconomic groups25-27. 
Smoking 
Both passive smoking and maternal smoking during pregnancy have been linked to an 
increased risk of the development of ARI, and increased risk of severe ARI requiring 
admission to hospital28 29. 
Air Pollution 
Air pollution has been reported as a risk factor for ARI for many years, with data from the 
1950’s during the ‘London fog’ suggesting increased mortality due to respiratory causes 
during that period30.  Indoor air pollutants such as the use of particular cooking fuels have 
also been shown to be risk factors of ARI in children. This is particularly relevant in 
developing countries, where biomass fuels are still commonly used, often in poorly 
ventilated settings, and may also be a contributing factor to the increased morbidity and 
mortality from ARI in developing countries31 32. 
HIV infection 
Human immunodeficiency virus (HIV) infection is an important risk factor for ARI, with the 
biggest impact being in Sub-Saharan Africa.  
 
5 
 
1.1.5 Aetiology 
Causative organisms are predominately bacterial or viral, with Streptococcus pneumoniae 
(S. pneumoniae) and Haemophilus influenzae type b (Hib) being the most common bacterial 
pathogens and hRSV, hRV, AdV, and parainfluenza virus (PIV) being the most commonly 
identified viruses33. 
1.1.5.1  ‘Typical’ Bacterial Pathogens 
Streptococcus pneumoniae 
Streptococcus pneumoniae (S. pneumoniae) is the most common cause of community-
acquired pneumonia worldwide34. It also causes meningitis and otitis media. S. pneumoniae 
is commonly carried in the nasopharynx of healthy individuals, with one particular study 
finding 26% of two month old infants, and 62% of two year olds to be carriers35. Problems 
arise when S. pneumoniae spreads from the nasopharynx to the lower respiratory tract 
causing pneumonia, or other sites such as the meninges, blood or middle ear, causing 
meningitis, bacteraemia or otitis media – these together are termed invasive pneumococcal 
disease34. Risk factors for carriage of S. pneumoniae include a young age, young siblings, 
day care attendance, asthma and, in adults, smoking34. Invasive pneumococcal disease is a 
huge problem, causing an estimated one million deaths in children under the age of five 
annually34. Human immunodeficiency virus (HIV) infection is an important risk factor for 
invasive pneumococcal disease, particularly in Sub-Saharan Africa. Those with HIV have a 
10-100 times increased risk of developing invasive pneumococcal disease when compared 
to the general population36.     
Haemophilus influenzae type b 
Haemophilus influenzae type b (Hib) is another leading cause of community-acquired 
pneumonia and meningitis, with the WHO estimating it caused 8.13 million serious illnesses 
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and 371,000 deaths in the year 200037. Successful Hib vaccines have been available for a 
number of years, and have led to dramatically reduced levels of Hib disease. A study 
published in 2009 estimated that in 2006, 55% of children in the world were included in Hib 
vaccination programmes. However, it is in a number of less developed countries where the 
vaccine is not routinely given, where Hib is still a major problem. It is estimated that 61% of 
all Hib childhood deaths occur in just 10 countries in Asia or Africa38. 
1.1.5.2 ‘Atypical’ Bacterial Pathogens 
‘Atypical’ bacterial pathogens are so called due to their ability to cause atypical pneumonia 
– pneumonia with symptoms different from those caused by S. pneumonia, including a sub-
acute onset, low-moderate grade fever, dry cough, prominent constitutional symptoms, 
absent or moderate leukocytosis and more extensive radiographic involvement than would 
be expected after physical examination39. The three most important atypical bacteria are 
Mycoplasma pneumoniae (Mpp), Chlamydia pneumoniae (Cpp), and Legionella40. 
Mycoplasma pneumoniae 
Mycoplasma was first described in 194441, but was classified as Mycoplasma pneumoniae 
(Mpp) by Chanock et al in 196342. It is estimated that Mpp may cause between 14 and 34% 
of lower respiratory tract infections in children, but it is generally accepted that it is more 
commonly associated with disease in older children and adolescents43 44, and is thought to 
be the most common cause of community acquired pneumonia in the 5-20 age group40. 
Studies specifically investigating children under the age of five with ARI have found Mpp 
rates to be between 0 and 1.5%10 45 46. 
Chlamydia pneumoniae 
Chlamydia pneumoniae (Cpp) is Gram negative, intracellular bacterium that, like other 
respiratory pathogens, may be responsible for a host of respiratory symptoms. Cpp has 
been found to be associated with between 6 and 20% of cases of community acquired 
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pneumonia40. Few studies have investigated the role of Cpp in children under the age of 
five, but those that have found rates of 0-1.3%10 45. 
Legionella 
Legionella is a Gram negative bacterium that was first named after an outbreak at an 
American Legion convention in 197647, although after identification previous outbreaks 
without known aetiology were discovered to have been caused by species of Legionella48. 
Legionella is usually transmitted by direct inhalation from contaminated water supplies, 
usually man-made reservoirs, where the bacterium thrives40. It causes a wide variety of 
clinical manifestations, from mild respiratory disease, to Legionnaires disease, with severe 
pneumonia and multisystem involvement, with neurological, hepatic and haematological 
abnormalities.  Legionella is thought to be associated with between 1 and 27% of 
community acquired pneumonias40, however it is very rare in young children, with most 
cases occurring in the immunocompromised, or those with risk factors such as prematurity 
or bronchopulmonary dysplasia48. 
1.1.5.3 Viral infection 
Human Respiratory Syncytial Virus 
Human respiratory syncytial virus (hRSV) is a single-stranded RNA virus of the 
Paramyxoviridae family, from the pneumovirinae subgroup. It gets its name from its ability 
to cause the cell membranes of nearby cells to fuse and form syncytia49. It is the most 
common cause of ARI in infants and young children, with almost all children having come 
into contact with the virus by the age of two years. One large study found hRSV to be 
responsible for 20% of hospitalisations, 18% of emergency department visits and 15% of 
general practitioner visits in children under five with ARI in the United States50. It is also 
thought to be responsible for 50-90% of hospitalisations for bronchiolitis51. 
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There are many other respiratory viruses which have been implicated in the pathogenesis 
of ARI. Influenza (flu), PIV, AdV, coronaviruses (CoV) and hRV have all been accepted as 
common aetiological agents, and have been found in varying prevalences in populations of 
children and adults with ARI. 
Rhinoviruses 
Rhinoviruses have been found to cause about two-thirds of common colds and asthma 
exacerbations in adults and older children52. Previous work has shown rhinoviruses have 
optimum replication temperatures of 33oC – the temperature in the nasal passages, as 
opposed to the higher temperatures in the lower respiratory tract, another factor in 
support of rhinoviruses being associated with upper respiratory tract infections (URTI) and 
the common cold. However, further research has shown that although the optimum 
temperature for hRV replication is 33oC, they are still able to replicate effectively at 37oC, 
proving it is feasible that they are a cause of lower respiratory tract infection53. 
Kusel et al. in 2006 detected hRV in 48% of nasopharyngeal aspirates from  children under 
the age of one year with ARI10, however this study population comprised children who were 
all at high risk of atopy (i.e. had at least one parent with asthma, eczema or hayfever), so 
results may not apply to general populations. Other studies looking specifically at children 
with ARI found the prevalence of hRV to be between 3.6 and 24.7%1 15 45 54. 
Adenovirus 
Adenovirus (AdV) infection can be classified according to over 50 different serotypes, which 
can be further divided into six main subgroups, each of which has some general clinical 
characteristics. AdV can cause a wide range of manifestations, with subgroups B1, C and E 
generally causing respiratory disease, subgroup F causing gastroenteritis, and subgroup D 
causing keratoconjunctivitis55. AdV infection of the respiratory tract can lead to a wide 
spectrum of disease from mild upper respiratory tract symptoms to severe pneumonia, 
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with one particular serotype (serotype 14) being associated with particularly severe disease 
and a high mortality rate56. 
Parainfluenza Viruses 
Parainfluenza viruses (PIV) are common causes of ARI, especially in children, with studies 
estimating that most children will have evidence of infection with multiple serotypes by the 
age of 557. 
 
Influenza Viruses 
Influenza (flu) viruses are responsible for between 250,000 and 500,000 deaths each year. 
Influenza A (flu A) viruses commonly cause pandemics, with the most recent being the 
novel H1N1 pandemic (commonly referred to as ‘Swine flu’), which was declared a public 
health emergency by the WHO on the 25th April 200958. H1N1 influenza presented in a 
similar way to seasonal influenza, but had increased occurrences of vomiting and diarrhea, 
and an increased number of hospitalisations and deaths, with young people being 
particularly affected58. Influenza B (flu B) is also an important cause of morbidity and 
mortality, however it generally causes milder disease, and is responsible for 75% fewer 
hospital admissions than flu A59.   
Coronaviruses 
Coronaviruses (CoV) are also a common cause of ARI, usually causing similar clinical 
manifestations to other previously mentioned viruses, with mild URTI being common. 
However, severe associated respiratory syndrome (SARS)-associated coronavirus was 
identified in 2002, which had particularly severe clinical manifestations, with some patients 
developing respiratory distress syndrome, requiring intensive care and ventilation57. 
Recently discovered viruses 
The discovery of new respiratory pathogens is not uncommon. Recently discovered 
respiratory pathogens include human metapneumovirus (hMPV), first identified in 200160; 
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two new coronaviruses, NL-63 (CoV NL-63), discovered in the Netherlands in 2004, and 
HKU-1 (CoV-HKU-1), discovered in Hong Kong in 200561 62; as well as human bocavirus 
(hBoV) discovered in Sweden in 200563. 
Human metapneumovirus 
Since discovery in 2001, hMPV has been shown to play a major role in ARI, being found in 
1.5-14% of samples from children with ARI1 33 45. Some studies have found that hMPV is 
associated with more severe disease when found in co-infection with hRSV64. 
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Human Bocavirus 
Human bocavirus (hBoV) was discovered by random polymerase chain reaction (PCR) 
amplification of respiratory samples from children63. Since its discovery it has been 
described by several groups worldwide, with prevalences in those with ARI being found to 
be between 1.5 and 18%, with detection most frequent in young children46 65. However, 
proving causality of hBoV in ARI has not been fully achieved, and it is still uncertain as to 
whether or not the detection of hBoV is clinically significant65-67. 
1.1.5.4 Tuberculosis 
Mycobacterium tuberculosis (TB) is an aerobic, acid-fast Gram positive bacillus which can 
infect all organs of the body, with pulmonary infection being most common68. Although 
vaccinations and treatment of TB have been successful, it is still a major global problem. 
Worldwide, 9 million new TB infections occurred in 2007, with 1.4 million of these being in 
those with HIV infection, most commonly in Africa (79%) or South-East Asia (11%)69. TB 
infection in children is usually due to close contact with an infected family member, and 
those with HIV infection or other form of immunocompromise are most at risk68. Infants are 
at the highest risk of developing disease after infection, as opposed to asymptomatic 
infection. Acute infections are most likely in the 3-12 months after initial infection, and may 
present with cough, fever and lymphadenopathy, as well as complications such as miliary 
TB where the bacterium spreads through the bloodstream, and causes disseminated 
disease throughout the lungs, as well as TB meningitis68. In developed countries the 
incidence of TB in children may be as low as 10 per 100,000 population. In contrast, in 
South Africa in 1993 the incidence rates were 273 per 100,000 in males under the age of 
one, and 205 per 100,000 in females under the age of one, and in a particular Cape Town 
community in 1991 the TB rate in children under the age of four was 3588 per 100,00070. 
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1.1.5.5 Previous studies into aetiology 
Many previous studies have investigated the aetiology of ARI, looking at various 
populations and a varying number of pathogens. Table 1 outlines the findings of a selection 
of studies that have investigated the prevalence of a range of pathogens in ARI. The studies 
in the table have been included due to their populations being restricted to pre-school 
children. 
As well as indicating the % prevalence of each pathogen, the table highlights co-infection 
rates described in the studies. Since the introduction of multiplex PCR and its ability to 
simultaneously detect multiple pathogens within one sample, many studies have included 
co-infection rates in their analysis, with findings ranging from 4% to 33%10 15 33 45 46. 
One notable study that is not included in the table is that by Brunstein et al. They 
investigated the prevalence of 21 pathogens in 1742 samples, from a population made up 
of 80% adults and 20% children. They detected at least one pathogen in 68% of samples, 
with co-infection in 26.8%54. However, one of the pathogens included was S. pneumoniae, 
detected in 20% of the population, and in a high proportion of co-infections. The authors 
acknowledged the point that they were not able to tell if the S. pneumoniae positive 
samples were examples of carriage of the bacterium, or if it was actually causing disease54. 
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Table 1: Summary of a selection of studies investigating the epidemiology of ARI in pre-school 
children 
Note: All values shown are % prevalence. X indicates that the particular study did not test for that 
pathogen. (AdV, adenovirus; hBoV, human bocavirus; CoV, coronavirus; Cpp, Chlamydia 
pneumoniae; Flu, influenza virus; hMPV, human metapneumovirus; Mpp, Mycoplasma 
pneumoniae; PIV, parainfluenza virus; hRSV, human respiratory syncytial virus; hRV, human 
rhinovirus) 
  
Study Bharaj 
et al13 
2009 
Kaplan 
et al46  
Sung   
et al45 
2009  
Lambert 
et al71 
2007 
Souza  
et al15 
2003 
Canducci 
et al33 
2008 
Regamey 
et al1 
2008 
Kusel   
et al10 
2006 
Age Group 
(years) 
<5 <5  <5  <5  <2 <2  <1  <1 
Total +ve 35.2 78 47 74 43 46.6 79 69 
Co-infection 6.6 33 4 9.9 4.8 14 20 10.3 
AdV X 37 4.8 3.1 5.9 X 3 1.5 
hBoV  X 18 X X X 2.2 5 X 
CoV X 1.2 3.8 1.5 X 8.7 18 5.5 
Cpp X 4.5 0 X X X X 1.3 
Flu 3.0 0.6 10.6 3.7 3.0 X 4 4.5 
hMPV 3.7 2.5 1.5 3.7 X 14.3 13 1.8 
Mpp X 0 1.5 X X X X 1.4 
PIV 16.3 0 8.8 4.1 5.1 X 17 5.2 
hRSV 20.3 43 8.4 6.6 1.8 28 16 10.9 
hRV X 11 3.6 n/a 24.7 X 23 48.5 
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1.1.6 Clinical Manifestations of ARI 
The term ‘acute respiratory infection’ encompasses all infections of the respiratory tract, 
from a mild upper respiratory tract infection (URTI), to severe bronchiolitis or pneumonia. 
Diagnoses are usually made on clinical grounds, which are subjective, being dependant on 
the clinician involved, with lots of overlaps between different clinical diagnoses. 
1.1.6.1 Upper Respiratory Tract Infection  
URTI are very common, and usually mild, with the common cold being the most common 
manifestation. Other manifestations classed as URTI include otitis media, croup, whooping 
cough and epiglottitis. 
Otitis Media 
Otitis media describes infection or inflammation of the middle ear, and is very common,  
affecting over 80% of children by the age of three years72. Symptoms of otitis media include 
ear-ache, which in a young child may present with them being irritable and tugging at one 
or both ears, fever, loss of balance and a degree of hearing loss. It is thought that up to one 
third of cases of otitis media are caused by S. pneumoniae73. 
Croup  
Laryngotracheobronchitis, or croup, describes inflammation of the larynx and trachea. It 
causes hoarseness and a loud, harsh, barking cough. It can also cause stridor, commonly 
when the child becomes upset, but also in more severe disease. The most common cause of 
croup is PIV infection, but it can also be caused by other respiratory pathogens74.  
Whooping cough 
Pertussis, or whooping cough, is so called due to the ‘whooping’ sound made during the 
inspiration of air against a closed glottis after a bout of coughing. It is caused by the Gram 
negative bacterium Bordetella pertussis. The main symptom is bouts of coughing, often 
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ending in vomiting. The illness is usually mild, although it can be severe in young children, 
and can last for a prolonged period of time74.  
Epiglottitis  
Epiglottitis is a particularly serious manifestation of URTI. It describes inflammation of the 
supraglottic larynx, usually caused by Haemophilus influenzae type b. It is characterised by 
acute onset stridor, and can rapidly cause obstruction of the trachea, meaning prompt 
management is vital74. 
1.1.6.2 Bronchiolitis 
Bronchiolitis predominately affects infants and young children, with the main clinical 
features being initial coryza, developing into cough, with the presence of wheezing and/or 
crackles and signs of respiratory distress, such as tachypnoea, hyperinflation and recession, 
commonly complicated by acute otitis media75 76. 
1.1.6.3 Pneumonia 
Pneumonia describes inflammation of the parenchyma of the lung77. In children the signs 
and symptoms include fever, tachypnoea and respiratory distress, often with focal or 
diffuse crackles on auscultation. In young children pneumonia is commonly caused by both 
bacteria and viruses, with S. pneumoniae being the most common bacterial cause78.   
1.1.6.4 Episodic Viral Wheeze/Asthma 
Wheeze can be defined as ‘a continuous high-pitched sound with musical quality emitting 
from the chest during expiration’, and is caused by limitation to the airflow during 
expiration79. Episodic viral wheeze (EVW) can be described as ‘wheezing during discreet 
time periods, often in association with clinical evidence of a viral cold’79. Episodic viral 
16 
 
wheeze is most common in children under five, and usually disappears by the age of six, 
although it may continue79. The Global Initiative for Asthma (GINA) has described asthma as 
‘a syndrome with a highly variable clinical spectrum, characterised by airway inflammation’. 
However, the presence of inflammation is difficult to determine in very young children, so 
EVW is a more accurate description, until symptoms can be more accurately assessed when 
the child is older, and if necessary a diagnosis of asthma can be made79.  
1.1.7 Investigations 
The diagnosis of ARI is a clinical one, based on history and physical examination findings. 
Specific diagnoses such as URTI, bronchiolitis, pneumonia, and episodic viral wheeze are 
used and do have an impact on management, with children diagnosed with pneumonia 
being more likely to be given antibiotics than children diagnosed with bronchiolitis, which is 
presumed to be viral. 
There are many techniques available for the detection and identification of pathogens 
responsible for ARI. Studies have shown major advantages to viral identification80. 
Knowledge of the correct diagnosis helps determine the optimum management of the 
infection, decreasing morbidity and mortality. Studies have shown decreased antibiotic use 
and shorter hospital stays, with children with proven viral pathogens not being given 
unnecessary antibiotics81. Viral identification is also used to separate children infected with 
particular pathogens76, allowing uninfected children, and particularly vulnerable children, 
such as those with congenital cardiac and respiratory problems, to be protected from 
exposure.  
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Sampling Techniques 
The British Thoracic Society guidelines on community acquired pneumonia state that all 
children suspected of having bacterial pneumonia should have blood cultures taken, and all 
children under the age of 18 months should have a nasopharyngeal aspirate (NPA) taken 
for viral antigen detection with or without viral culture78.  
Obtaining a nasopharyngeal aspirate involves inserting a catheter between five and seven 
centimeters into the child’s nostril, then pulling back on the catheter while applying gentle 
suction82. An alternative method involves taking a nasal swab, where a cotton swab is 
inserted around 1.5 centimeters into the nostril and rotated against the nasal cavity to 
obtain a sample83. Taking a nasal swab is quicker, less invasive and less uncomfortable for 
the child. However, several studies have found that the sensitivity of detection of 
respiratory viruses is higher in NPA samples when compared to nasal swabs82-84. 
The other problem with sampling using NPAs or nasal swab samples, is that in both cases, 
the sample is being taken from the upper respiratory tract, rather than the lower 
respiratory tract where the infection is causing the clinical manifestations of disease.  
Bronchoalveolar lavage (BAL) is a way of obtaining fluid from the lower respiratory tract, 
and although this would make it ideal for the detection of pathogens which are causing 
lower respiratory tract infection, it is invasive and requires sedation, so is not a practical 
option for the majority of those with ARI. It does, however, have a place in severely ill 
children who are already ventilated, and non-bronchoscopic BAL may then be a practical 
way of detecting pathogens in the lower respiratory tract85.  
Pathogen detection 
Polymerase chain reaction (PCR) has been shown to be the gold standard in the rapid 
detection of respiratory viruses, and many advantages over other methods have been 
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described. More traditional methods include virus culture and antigen detection. However, 
virus culture can take between 2 and 14 days to obtain results86, so in most cases would not 
be of much use in guiding the management of a patient. Antigen detection methods such as 
enzyme immunoassay are quicker than virus culture and results can be available in less 
than 24 hours. However, the sensitivity and specificity of PCR has been found to be greater 
than that of other methods86 87. PCR will be discussed in more detail in the methods section. 
Chest Radiographs 
In ARI decisions about antibiotic use are often based on radiographic findings, with signs of 
consolidation on chest x-ray being presumed to be caused by bacteria and thus treated 
with antibiotics. Studies have shown that the use of chest radiographs are associated with 
increased likelihood of antibiotics and longer stays in hospital. One study randomised 
children with ARI to receive or not receive a chest x-ray, and found that children who 
received a chest x-ray were more likely to be diagnosed with having bacterial pneumonia or 
lower respiratory tract infection and treated with antibiotics, although the median time to 
recovery was the same in both groups88. This study concluded that chest x-rays did not 
affect clinical outcome, and were not beneficial, in children over two months of age with 
acute lower respiratory infection88. 
Indicators of disease severity 
Perhaps more important than labelling a condition, is the ability to recognise more severe 
disease, or the potential to develop more severe disease. Several studies have investigated 
clinical predictors of disease severity in children with suspected bronchiolitis, with the most 
consistent finding being that oxygen saturations derived from pulse oximetry are the single 
most useful predictor of severe disease89 90. Other independent predictors of severe disease 
were found to be young age and young gestational age, as previously mentioned, and high 
respiratory rate90.  
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1.1.8 Management of the Clinical Manifestations of ARI 
The majority of children with ARI will have a mild, self-limiting illness and do not require 
any treatment. However, ARI can cause very severe infections, especially in the very young 
and those with other co-morbidities, leading to many hospital admissions each year. The 
mainstay of treatment is supportive, and includes the use of supplemental fluids and 
oxygen. 
1.1.8.1 Upper Respiratory Tract Infection 
Upper respiratory tract infection (URTI) is the most common manifestation of ARI, covering 
everything from the common cold to otitis media, croup, whooping cough and epiglottitis. 
The common cold requires supportive treatment, making sure the child is kept well 
hydrated, and the use of anti-pyretics such as paracetamol for fever.  
Otitis Media 
The treatment of otitis media is debated. Untreated, bacterial otitis media can cause 
serious complications such as mastoiditis and chronic supperative otitis media leading to 
hearing loss. Because of the risk of these complications, and the fact that S. pneumoniae is 
responsible for around one third of cases of otitis media, antibiotics such as amoxicillin are 
often overprescribed, and this itself is causing problems by increasing bacterial resistance. 
Antibiotics may also cause adverse effects including diarrhea, vomiting, rashes and fungal 
infections91. Recent studies have investigated a ‘watch and wait’ strategy, in which children 
with less severe otitis media were given supportive treatment and followed up to assess for 
any worsening of symptoms, and then subsequently given antibiotics if necessary. The 
study found that 61% of children improved without antibiotics, and those that did need 
them were no more likely to have complications requiring surgery91. The study therefore 
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recommended that in children without any severe signs or symptoms, a ‘watch and wait’ 
strategy should be used, which will eliminate any adverse effects from antibiotic use, and it 
may help reduce antibiotic resistance91. 
Croup 
The management of croup is supportive, ensuring the parents are aware of signs of 
deterioration such as increasing respiratory rate, fatigue, chest-wall indrawing and a 
softening stridor. Severe disease may require intubation under general anaesthesia to avoid 
airway obstruction74.  
Whooping Cough 
The macrolide antibiotic erythromycin may be given to children in the early stages of 
Bordetella pertussis infection, although it is of little use once the paroxysmal cough has 
begun. It does, however, have a prophylactic use in contacts of someone with Bordetella 
pertussis infection. Treatment is otherwise supportive, with admission necessary in young 
children who are at risk from apnoea, and may require ventilation74. 
Epiglottitis  
Epiglottitis can be life-threatening and rapid management is vital. The throat should not be 
examined until an experienced anaesthetist is present. The throat can then be examined, 
and if a swollen, inflamed epiglottis is visible, the child should be intubated immediately 
under general anaesthetic. Haemophilus influenzae type b (Hib) is the most common cause 
of epiglottitis and a third generation cephalosporin such as cefotaxime should be 
commenced immediately74. The incidence of epiglottitis had dramatically decreased since 
the introduction of the Hib vaccine into immunisation schedules77.   
21 
 
1.1.8.2 Bronchiolitis 
The mainstay of treatment for bronchiolitis is supportive. Oxygen should be given if 
saturations are below 93%, if the child has severe respiratory distress or if the child is 
cyanosed. Adequate hydration should be maintained, and if this is not possible through oral 
feeding nasogastric feeding or the use of intravenous fluids should be considered92.  
Bronchodilators are widely used in the treatment of ARI76. However, a Cochrane review 
investigating evidence for the use of bronchodilators in bronchiolitis found that although 
bronchodilator therapy led to a significant improvement in clinical scores, it recognised that 
the studies had included children with recurrent wheeze or asthma, which may have 
skewed the results93. This study also found no difference in rates of hospitalisation or 
oxygen saturations in those who had been given bronchodilators compared to controls93. A 
more recent systematic review found similar results, with studies finding improvements in 
short-term clinical measurements in children receiving bronchodilators, but no difference in 
the need for hospital admission or duration of hospital stay94. As with all pharmacological 
treatments, bronchodilator therapy is not without adverse effects, and these include 
increased heart rate and temporarily decreased oxygen saturations95. There is therefore 
little evidence supporting the use of bronchodilators for bronchiolitis, with only short term 
improvements in clinical measures being demonstrated.  
Many studies have investigated the use of corticosteroids in bronchiolitis. Two large studies 
reviewed the evidence available, and both concluded that although corticosteroids may 
improve short term clinical scores, they did not improve the need for hospital admission or 
length of stay, and are not indicated in bronchiolitis94 96. 
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1.1.8.3 Pneumonia 
Pneumonia may be viral or bacterial, and while viral pneumonia requires only supportive 
treatment, the correct treatment of bacterial infection is important. The British Thoracic 
Society guidelines suggest bacterial pneumonia should be considered in children less than 
three years if there is fever over 38.5oC, along with a respiratory rate greater than 50 
breaths per minute and chest recession, and that bacterial pneumonia is unlikely if wheeze 
is present78. Antibiotics are given according to local or national guidelines, which should 
take into account patterns of particular pathogens and resistance in that area. Current 
British Thoracic Society guidelines suggest that the most appropriate treatment for 
suspected bacterial infection in children under five is with amoxicillin, and in those with 
severe pneumonia co-amoxiclav, cefuroxime and cefotaxime are appropriate78. Macrolide 
antibiotics are only advised as first line treatment in children over the age of five, in whom 
infection with Mpp is more common78. Overuse of antibiotics, especially in viral infection 
when they are completely unnecessary, can lead to increased antibiotic resistance of 
bacteria, which is an important clinical problem. There is significant penicillin resistance to 
S. pneumoniae worldwide with the main risk factor being previous antibiotic use, and a 
further risk factor for penicillin resistant invasive pneumococcal disease being recent 
respiratory tract infection34.     
1.1.8.4 Episodic Viral Wheeze/asthma 
As well as supportive therapy such as fluids and oxygen when necessary, bronchodilators 
are the mainstay of treatment for acute episodes of wheeze. Inhaled, short-acting β2-
agonists are the first line treatment, giving rapid bronchodilatory effects and relief of 
symptoms. Adverse effects such as headaches and palpitations are rare with inhaled 
therapy unless particularly high doses are given79. 
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 Corticosteroids are often used during acute episodes of wheeze in children due to their 
proven role in acute exacerbations of asthma in adults and older children97. However, a 
recent review article looking into the results of several trials has found conflicting evidence 
on the use of corticosteroids in this age group, and recommended that a trial of oral 
corticosteroids should be given only children admitted to hospital with severe wheeze79.  
1.1.9 Prevention 
The burden of ARI is great on many levels, from its effects on individuals, to the large 
hospital costs from the high number of admissions that it causes each year. Due to the lack 
of effective treatment for ARI, with management being largely supportive, prevention may 
be key to decreasing the burden. Prevention of ARI can be viewed from two perspectives. 
Firstly, prevention can be attempted by addressing some of the risk factors mentioned in 
section 1.1.4. The biggest problem faced here is that many of the issues are already large 
health problems, which many countries are already attempting to address. Smoking 
cessation, for example, is the focus of many government schemes in both developed and 
developing countries. Although this may have a positive impact on the prevalence of ARI, 
the schemes are already large and costly and to further them specifically for the purpose of 
preventing ARI would not be feasible. Poverty is the other major risk factor that contributes 
to ARI. Again, this is a global problem for which there is not an easy solution.  
1.1.9.1 Prophylaxis 
Prophylaxis is the other major route to prevention of ARI. However, there are some 
considerable problems with the development of suitable vaccines for ARI. The first and 
biggest problem lies in the varying aetiology of ARI – many pathogens, both viral and 
bacterial, are responsible for ARI. It would not be feasible to attempt to develop 
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vaccinations, or vaccinate against a large number of pathogens that in most cases cause 
mild, self-limiting illnesses.  
hRSV prophylaxis 
It is not surprising that most efforts to develop a vaccine have been focused on hRSV 
infection, as it has been shown to cause 50-90% of hospitalisations for bronchiolitis and 20-
50% of hospitalisations for winter pneumonia. The development of hRSV vaccination has 
been slowed by safety issues following the administration of a formalin-inactivated hRSV 
vaccine to 13 residents of a children’s home in 196698. An outbreak of hRSV infection at the 
centre approximately nine months following the vaccinations, demonstrated that the 
children who had received the vaccinations were not only not protected against hRSV, but 
developed more severe disease, with significantly higher rates of hospitalisation, higher 
rates of pneumonia, and longer duration of illness98. A breakthrough in immunisations 
against hRSV occurred with the development of Palivizumab, a humanised monoclonal 
antibody, which has been shown to significantly reduce hospitalisations in children at high 
risk of hRSV infection99 100. Palivizumab is given monthly as an intramuscular injection to 
high risk infants during the hRSV season. Although Palivizumab has been shown to be 
clinically effective at reducing hospitalisations in high-risk infants, the cost of vaccinating 
these infants is very high, and studies have found the use of palivizumab is not cost 
effective in all high risk children101. 
Pneumococcal conjugate vaccine 
The heptavalent pneumococcal conjugate vaccine (PCV7) was introduced in the year 2000, 
vaccinating against the seven most common serotypes of S. pneumoniae. In the USA all 
children under the age of two receive the vaccine, as well as children under five who are at 
an increased risk of invasive pneumococcal disease. The vaccine has been shown to reduce 
invasive pneumococcal disease, as well as nasopharyngeal carriage of these serotypes of 
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the bacteria in both children and adults102-104. Large studies have found reduced rates of 
meningitis and invasive pneumonia that have been sustained in the years since the vaccine 
was introduced105. Although the vaccine has been shown to be effective at preventing cases 
of invasive pneumococcal disease caused by the seven common serotypes, since the 
introduction of the vaccine, the presence of invasive disease caused by other non PCV7 
serotypes has increased dramatically, with a higher percentage of these being resistant to 
penicillin as well34. Similarly, a large study in Massachusetts found that after introduction of 
the vaccine there was very little carriage of any of the PCV7 serotypes, but greatly 
increased carriage of the non-PCV7, often penicillin resistant serotypes106. Invasive 
pneumococcal disease therefore remains an important problem causing significant 
mortality worldwide. More recently, a 13-valent pnumococcal conjugate vaccine (PCV13) 
has been introduced into the vaccination schedules, replacing PCV7. It was introduced in 
the US in February 2010, shortly followed by the UK in April 2010, protecting against 13 
strains of the bacteria, which are responsible for three-quarters of invasive disease in young 
children, although as with PCV7, the prevalence of non-PCV13 serotypes is likely to 
increase107.  
1.1.10 Sequelae of ARI 
Although the immediate morbidity and mortality associated with ARI comes from the acute 
illness, there is a wealth of literature investigating associations between viral infection in 
infancy or childhood with respiratory problems later in life, such as recurrent wheeze and 
asthma, or with an increased likelihood of developing invasive pneumococcal disease.  
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1.1.10.1 Recurrent Wheeze 
Several studies have investigated the development of wheezing and asthma in children who 
had a viral respiratory illness, often focusing on particular viruses or particularly severe 
disease. One large study by Jackson et al in 2008, found that rhinovirus infection causing 
wheezing in the first three years of life, but especially in the third year, was strongly 
associated with an increased risk of asthma by the age of six (odds ratio = 9.8)108. They also 
found increased asthma at age six in children who had had wheezy illness caused by hRSV 
infection in the first  three years of life, although this association was not as strong (odds 
ratio = 2.6)108. A limitation to this study is that all study participants were at high risk of 
asthma development – in order to be eligible for inclusion into the study the child must 
have one parent with proven allergen sensitivity or diagnosed asthma108. Sigurs et al in 
2009 reported asthma/recurrent wheezing, allergic rhinoconjunctivitis and sensitisation to 
common inhaled allergens were all significantly more frequent in a group of children who 
were hospitalised with hRSV bronchiolitis in infancy, when compared to matched 
controls109. Stein et al in 1999 found an association between hRSV LRTI before the age of 
three, and wheeze up until the age of 11. However, after age 11 the risk decreased and 
unlike the previously mentioned studies, was not significant by the age of 13110.    
Although all these studies show significant associations between ARI in infancy or childhood 
and the development of further respiratory morbidity, no causal relationship has been 
established. As mentioned in the study by Jackson et al. their results indicate that 
rhinovirus infection in infancy may be used as a predictor of asthma later in childhood108. It 
is not known whether these infections predispose to later illness and the development of 
recurrent wheeze or asthma, or whether these children may already be predisposed to 
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developing recurrent wheeze or asthma and, for the same reason, are at higher risk of 
having a viral respiratory illness.  
1.1.10.2 Invasive pneumococcal disease 
A study by Ampofo et al found that viral infection with hRSV, influenza or hMPV was 
associated with increased risk of admission with invasive pneumococcal disease in the 
weeks following the viral infection. The increased risk existed for four weeks after hRSV 
infection, and two weeks after influenza or hMPV infection111.  In a large study of adults and 
children with invasive pneumococcal disease in New Zealand, Murdoch et al. found 
statistically significant correlations between incidence rates of invasive pneumococcal 
disease and detection rates of flu viruses, AdV and PIV3, and in the under 5’s RSV112. 
Madhi et al found that a pneumococcal conjugate vaccine introduced in South Africa 
prevented nearly one third of ARI caused by influenza A, RSV, PIV 1-3 and AdV. This 
highlighted the importance of viral-bacterial co-infection, and its role in causing disease, as 
well as the role of pneumococcal vaccination in the prevention of viral ARI as well as those 
caused directly by Streptococcus pneumoniae 113.  
1.1.10.3 Bronchiolitis obliterans 
Bronchiolitis obliterans describes a pathological process in which inflammation and fibrous 
tissue deposition lead to the obstruction and obliteration of the terminal and respiratory 
bronchioles85. It is associated with a number of conditions, including toxic fume inhalation, 
graft-vs-host disease after transplants, drugs such as penicillamine, and post-infection 
following acute respiratory infection114. Specifically, particular types of AdV – 1, 3, 7 and 21, 
as well as influenza virus, Mpp and Legionella infection are associated with a risk of 
developing bronchiolitis obliterans114. The prognosis of bronchiolitis obliterans is variable, 
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with some patients having a rapidly declining lung function with a fatal outcome, while 
some patients develop chronic lung disease and others have actually improved over time, 
with gradual resorption of the fibrovascular tissue and improvement to almost normal 
airways and lung function114.   
1.1.10.4 Bronchiectasis 
Bronchiectasis describes chronic dilation of the airways and thickening of the bronchial 
walls115. This in turn leads to destructive changes and abnormalities in the epithelium, with 
loss of cilia giving a decreased ability to clear secretions and mucus gland hyperplasia 
leading to increased sputum production115 116. Ultimately this causes an increased likelihood 
of chronic infection, chronic inflammation and airway obstruction115.  There are a many 
causes of bronchiectasis, including post-infectious, congenital, immunodeficiencies, ciliary 
abnormalities, as well as foreign body aspiration, toxic gas inhalation and asthma116. Post-
infectious causes relevant to this study of ARI include AdV, Mpp, Bordetella pertussis, TB 
and necrotizing bacterial pneumonia116. Clinical features of bronchiectasis include chronic 
cough, large amounts of sputum production and recurrent infections116. Management of 
bronchiectasis involves treating the underlying cause, using postural drainage to remove 
mucus, vaccinating against infectious agents where possible and prompt antibiotic 
treatment of new infections. Surgical interventions such as pneumonectomy are used for 
localised disease which is causing severe symptoms116.      
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1.2 Immunological responses to ARI 
The lung makes up the largest epithelial surface in the body, with each breath exposing the 
airways to new micro-organisms which may give rise to acute respiratory infection117.  As 
well as the need for a rapid acting, efficient immune system to deal with these micro-
organisms, the complex physiology of the respiratory system, with its ability to facilitate gas 
exchange, is a delicate, balanced environment, in which an inflammatory response, aimed 
at destroying a potentially harmful pathogen, may itself create problems and affect the 
normal functioning of the lung118. 
The immune response can be divided into the innate and the adaptive responses. The 
innate response comprises rapid, first line, non-specific mechanisms in the defence against 
infection by pathogens. The adaptive response is in contrast, a much more complex system, 
with specialised cells mounting specific responses against the particular pathogen involved 
in each ‘attack’, and producing an immunological ‘memory’ to enable the rapid elimination 
of that particular pathogen should it come into contact with the host immune system on a 
subsequent occasion. However, the adaptive immune system’s specificity, although 
essential, can take three to five days to produce an adequate response to effectively deal 
with a pathogen, a time when the innate immune system plays a vital role in controlling the 
replication of the pathogen, and limiting its damaging effects119.  
1.2.1 Innate Response 
As already mentioned, the innate immune response is the earliest line of defence against 
infection, and plays an important role in the initial response to a pathogen. However, the 
innate immune system also has another major role in the activation of the adaptive 
immune response, which will be discussed further at a later stage.   
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Innate immunity can be divided into three groups, the physical barriers to infection, the 
non-cellular response and the cellular response.  
1.2.1.1 Physical Barriers to Infection 
Physical barriers to infection are the very first line of defence any invading organisms will 
encounter, and include the cough reflex, the barrier function of respiratory epithelium and 
the muco-ciliary escalator. The respiratory epithelium is highly specialised, with numerous 
roles in the protection of the respiratory tract from invasion by pathogens, but firstly, it 
provides a physical barrier to foreign particles and pathogens. The epithelium also plays a 
pivotal role in the muco-ciliary escalator, with pseudostratified columnar epithelial cells, 
which form a large part of the epithelial surface of the conducting airways, being ciliated 
cells. The co-ordinated beating of the cilia on these cells provides a mechanism for clearing 
mucus and with it any trapped material, out of the airways, to the epiglottis, where it can 
be safely swallowed, clearing any potential pathogens away from the delicate respiratory 
surfaces120. 
Mucus has several roles including the lubrication of mucosal surfaces, and the 
immunological functions of trapping inhaled particles or organisms in order to clear them 
from the respiratory system. Mucus is made up of water, ions, proteins, lipids and 
‘mucins’121. Mucins are large gel-forming glycoproteins that give mucus its gel-like 
properties, and its ability to trap bacteria. Mucus, however, can also play a major role in 
pathological processes, with cystic fibrosis being a prime example, when the mucus is 
dehydrated, causing thick purulent sputum, providing an environment that traps 
pathogens, which, because of the increased viscosity, are not cleared by the muco-ciliary 
escalator, giving a high risk of infection. Pathogens such as bacteria and viruses themselves, 
along with the release of inflammatory mediators in response to infection have been shown 
31 
 
to influence and increase mucus production, leading to some of the clinical manifestations 
associated with respiratory illness. 
For pathogens that get past the initial physical barriers of the respiratory tract, the next line 
of defence comprises soluble mediators of the immune system that can be found in the 
fluid lining the respiratory tract – the airway surface fluid (ASF)117.  
1.2.1.2 Pathogen recognition/detection 
The ability to recognise a pathogen in order to initiate an immune response is the first, vital 
role of the immune system. The innate immune system uses a range of genetically pre-
programmed receptors, which, instead of being able to recognise specific pathogens, like 
the adaptive immune system, are able to recognise structures or patterns common to many 
pathogens, which, importantly, are absent in self molecules. These structures are called 
‘pattern-associated molecular patterns’ or PAMP’s, and the receptors are called ‘pattern 
recognition receptors’ (PRR’s)119.  Examples of PAMP’s are lipopolysaccharide (LPS), an 
endotoxin and component of the cell membrane of gram negative bacteria; forms of 
bacterial DNA – unmethylated cytosine-guanosine-rich areas – CpG sequences; and double 
stranded RNA117 119. 
Pattern Recognition Receptors 
Pattern recognition receptors (PRR’s) are proteins that are expressed on cells of the innate 
immune system, such as macrophages, dendritic cells and B-cells. PRR’s can be divided into 
secreted, endocytic or signalling PRR’s. Secreted PRR’s act as opsonins, which find and bind 
to pathogens in order to alert other cells of the immune system to their presence, so an 
appropriate response may be mounted. Endocytic PRR’s are found on the surface of 
phagocytes, mediating the delivery of pathogens to lysosomes, where they are destroyed. 
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Signalling receptors recognise PAMP’s and activate pathways that lead to the transcription 
of many genes vital to an effective immune response119. 
Toll like receptors 
Toll-like receptors (TLR’s) are a family of signalling PRR’s that upon recognising a particular 
PAMP, activate pathways that result in the transcription of inflammatory mediators. These 
mediators, such as inflammatory cytokines, not only play a major part in the initiation of 
the innate inflammatory response, but are vital in the initiation of the adaptive response119.  
At present, there are 10 known toll-like receptors in humans, and 12 in mice122. The TLR’s 
can be divided according to whether they are found on cell surfaces (TLR1, TLR2, TLR4, TLR6 
and TLR11), or in intracellular vesicles (TLR3, TLR7, TLR8 and TLR9), such as in lysosomes, 
where they recognise microbial nucleic acids122. Different TLR’s have are activated by 
different PAMP ligands, and then activate specific pathways resulting in the production of 
specific inflammatory mediators. The general pathway used by the TLR’s involves activation 
of nuclear factor κB (NF-κB) transcription factors using various pathways according to the 
specific TLR and ligand. The NF-κB is released and enters the nucleus, initiating the 
activation of a range of inflammatory genes119.  The toll-like receptors also play a vital role 
in the activation of the adaptive immune system, with T-cells (whose functions will be 
discussed in section 1.2.2.2), needing both an antigen against which to mount a response, 
as well as the expression of CD80 or CD86 molecules on an antigen presenting cell, in order 
for the T-cell to be activated. The TLR’s induce the expression of the CD80 and CD86 
molecules119. This is important not only for activation of the adaptive immune response, 
but also to ensure that the adaptive immune response occurs only when necessary. The 
activation of TLR’s, and the subsequent expression of CD80 or CD86 only when infection is 
present, is a vital mechanism in the prevention of an immune response against self 
molecules119. 
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Several TLRs are involved in the recognition of pathogens which cause ARI. TLR-2 is known 
to recognise bacteria, including Mpp, as well as viruses, and is able to initiate different 
responses depending on the particular ligand it comes into contact with by forming 
heterodimers with other TLRs123. TLR-4 has also been shown to be important in the 
recognition of respiratory pathogens. As well as recognising bacteria, it has been found to 
be important in the recognition of hRSV, as well as being implicated in the pathogenesis of 
H5N1 avian influenza. It is thought that TLR4 recognises one of the molecules released from 
cells damaged by H5N1 (a damage-associated molecular pattern, DAMP), and mice 
deficient in TLR-4 were found to be resistant to the H5N1 induced lethality123. This 
illustrates one example of the immune response being damaging rather than protective.  
Collectins 
Collectins are secreted pattern recognition receptors which bind to carbohydrates on 
pathogens including gram negative and gram positive bacteria, and some viruses, parasites 
and yeasts. Examples of collectins include mannan-binding lectin (MBL) and surfactant 
proteins A and D. The main functions of these are to alert and recruit other cells of the 
immune system, such as macrophages and lymphocytes, and to activate the ‘lectin 
pathway’ in which the activation of a series of proteases leads to the activation of the 
complement pathway – one of the effectors of the innate immune system119. The 
surfactant proteins are also particularly important in the regulation of inflammation in the 
lungs, inhibiting the activation of alveolar macrophages until they themselves come into 
contact with a pathogen118. 
Lysosome 
Endocytic pattern recognition receptors are proteins attached to the surface of phagocytes 
which mediate the uptake and delivery of pathogens to lysosomes, which endocytose 
(engulf) the pathogens, and destroy them using acid hydrolases.  Proteins from the 
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pathogen are then processed and displayed on the surface of the phagocyte by major 
histocompatability complex (MHC) molecules, in order to alert the adaptive immune 
system, which will be described later119.  
1.2.1.3 Soluble mediators of the innate immune system 
Defensins 
The defensins are small peptides found in the respiratory tract, as well as the gastro-
intestinal and reproductive tracts. The α-defensins are produced by neutrophils, and the β-
defensins are produced by epithelial cells124. They have broad antimicrobial activity against 
bacteria, fungi and some viruses117. The antimicrobial action of defensins relies upon 
attachment to the cell membrane, where it is thought they then form pores in the 
membrane124. They are also able to activate the alternative complement cascade, which will 
be discussed in more detail in section 1.2.1.4.  The defensins have been shown to be up-
regulated in response to epithelial cell exposure to pathogens, TLR agonists and 
inflammatory cytokines125. Murine studies have found that mice deficient in β-defensin had 
delayed clearance of Haemophilus influenzae from the lung after infection126, and also that 
mouse β-defensin inhibits influenza A replication127, both studies suggesting defensins may 
have an important role in the defence against ARI.  
Lysozyme 
Lysozyme is found in airway lavage fluid and sputum. They are enzymes which are made by 
glandular serous cells, surface epithelial cells and macrophages, and are highly effective at 
defending the airway against Gram-positive bacteria117. They are effective by catalysing 
hydrolysis of peptoglycan links in the bacterial cell wall. They are also implicated in 
neutrophil recruitment117.  
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Lactoferrin 
Lactoferrin is another broad-spectrum, anti-microbial protein found in high concentrations 
in lavage fluid120, but is probably better known for its high concentration in colostrum and 
breast milk, where it provides important anti-microbial activity to infants.  In the lungs it is 
produced by serous cells and neutrophils. Lactoferrin’s antimicrobial activity is based on its 
ability to cause agglutination of bacteria, upon recognising them by their carbohydrate 
motifs117, as well as its ability to remove iron from pathogens125  .  
Increased amounts of both lysozyme and lactoferrin have been detected in the lungs of 
mice after treatment with Haemophilus influenzae, as well as other infectious agents, 
implicating them in the immune response to ARI, although further details on specific modes 
of action against specific pathogens are not known125. 
Immunoglobulin A 
Immunoglobulins are secreted by B-lymphocytes, and while these are usually associated 
with the adaptive immune response, immunoglobulin A (IgA) release has been shown to be 
stimulated by the release of stimulatory cytokines from epithelial cells. IgA is found in the 
secretions of the respiratory tract, as well as the gastro-intestinal tract, genito-urinary tract, 
breast milk and colostrum, and is important in the rapid response, especially to viruses117. 
Type I Interferon Response 
The type I interferon (IFN) response is particularly important in the defence against viruses, 
with the name describing the ability to interfere with viral infection128. IFN-α and IFN-β are 
the most important IFN’s in the response, and are released by numerous cells of the innate 
immune system, including epithelial cells, particularly in response to NF-κB, and by 
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macrophages, in response to viral infection117. Mice deficient in receptors for type I 
interferons have shown increased viral replication in the lung, although the infection was 
still cleared by other mechanisms, illustrating the complexity of the immune response with 
various different levels of defence117. 
1.2.1.4 Effectors of innate Immunity 
The complement system 
The complement system consists of a number of plasma proteins that may be activated by 
one of three pathways: the classical pathway, the alternative pathway, and the lectin 
pathway. Once activated these pathways lead to a number of steps which eventually all 
result in destruction of the pathogen with the formation of membrane attack complexes 
(MAC); or opsonisation of the pathogen for destruction by other parts of the immune 
system. 
The classical pathway, named due to its earlier discovery than the other two pathways, is 
activated by certain antibody-antigen complexes, and is a major component of the adaptive 
immune system. 
The adaptive and lectin pathways are both components of the innate immune system. The 
alternative pathway is activated by microbes themselves, without the need for antibodies. 
The activation takes place on the surface of the microbes, in the absence of regulatory 
proteins that prevent the activation on human cells. The complement protein C3b binds to 
the microbial cell surface, and plasma protein factor B is cleaved and forms the complex 
C3bBb – C3 convertase. C3 convertase leads to further cleavage of C3, amplifying the 
response and leading to more C3b, and the release of C3a. The C3b binds to the C3 
convertase, forming the alternative pathway C5 convertase129. 
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The lectin pathway was briefly mentioned earlier in the chapter. Lectins such as the 
mannan binding lectin (MBL), bind to polysaccharides on bacteria, as well as MBL-
associated serine proteases (MASPs), including MASP-1, MASP-2 and MASP-3. The 
subsequent complexes activate the lectin pathway by initiating the cleavage of C4 to C4b 
and C2 to C2b, forming the complex C4bC2b – C3 convertase, which, as in the alternative 
pathway, cleaves C3 to C3b. The C3b this time forms a C4b2b3b complex – another 
(classical) form of C5 convertase129.  
Both these pathways, as well as the classical pathway, lead to the formation of C5 
convertase. C5 convertase initiates the activation of further components of the 
complement cascade, including C6, C7, C8 and C9, which ultimately lead to the formation of 
the membrane attack complex (MAC). The MAC has the ability to form pores in the cell 
membrane, causing cell lysis129.  
Other functions of complement activation include opsonisation and stimulation of the 
inflammatory response. Opsonisation occurs when the pathogen becomes coated in C3b or 
C4b, both of which bind to receptors on neutrophils and macrophages, and initiate 
phagocytosis of the pathogen128. 
The C3a, C4a and C5a fragments released during the cleavage of C3, C4 and C5, 
respectively, have their own function in the stimulation of the immune response. C5 is the 
most potent, causing mast cell degranulation and stimulating neutrophil motility and 
adhesion to endothelial cells. C3b and C4b have similar effects but are less potent128 130. 
Phagocytes 
Neutrophils and macrophages are important effectors in the innate immune response to 
infection. They are phagocytes, their role being to recognise, internalise and subsequently 
destroy pathogens or particulate matter that is potentially harmful130.  They are also 
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important antigen presenting cells (APC’s), having a vital role in the activation of the 
adaptive immune system. 
Neutrophils 
Neutrophils are the most numerous circulating leukocytes, and are constantly produced in 
the bone marrow. Production and release of neutrophils is stimulated by granulocyte 
colony-stimulating factor (G-CSF). Neutrophils circulate in the blood, and in the absence of 
infection they will undergo apoptosis and phagocytosis after a period of around six hours130. 
However, when infection is present, neutrophils migrate to the site of infection, in response 
to the release of mediators such as IL-8, particular complement proteins and chemokines. 
This is very true in the lung during hRSV infection, with neutrophils accounting for 93% of 
cells taken from the upper respiratory tract, and 76% in the lower respiratory tract131. The 
process of neutrophil recruitment can be divided into a number of steps and begins with 
adhesion of the neutrophils to the endothelial surface, followed by migration through the 
endothelial cells towards the site of infection. Once reaching the site of infection, the 
neutrophils are kept in place, fulfilling their function as important phagocytes130.  
At the site of infection, neutrophils engulf potentially harmful organisms and destroy them 
via a number of mechanisms, including the use of reactive oxygen species, antimicrobial 
proteins, and degradative enzymes118. Neutrophils also have important roles in the 
production of pro-inflammatory mediators. They produce pro-inflammatory chemokines 
and cytokines, such as IL-1 and TNF-α, which encourage further neutrophil recruitment; and 
other mediators such as chemerin which activates dendritic cells; B-lymphocyte stimulator, 
stimulating B-cells and IL-12 - an important activator of T-cells. So neutrophils do not only 
further stimulate innate response, but play an important role in the activation and 
manipulation of the adaptive immune response130. 
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During infection there is rapid proliferation and migration of neutrophils to the affected 
tissue, in response to the release of a variety of mediators, one of the most important being 
IL-8. IL-8 is released by macrophages and epithelial cells in response to infection, with initial 
responses being incredibly rapid. Studies of respiratory epithelial cells have shown IL-8 
responses initially peaking within two hours of infection with hRSV132. IL-8 release by 
macrophages and epithelial cells is stimulated by TNF-α and IL-1133, both of which are 
produced by macrophages in the early immune response to pathogens. IL-8 causes a rapid 
accumulation and activation of neutrophils, with neutrophils being abundant and IL-8 
concentrations being increased in respiratory samples from patients with ARI. Recent 
studies, however, have implicated IL-8 in the pathogenesis of ARI, particularly in hRSV 
disease. An association between severe hRSV bronchiolitis and a polymorphism near the IL-
8 gene was detected, with those with the polymorphism having increased IL-8 levels, and 
increased severity of disease134. This will be discussed further in section 5.4.1.   
Macrophages 
Macrophages are also important phagocytes, but they have some major differences in their 
functions. Whereas neutrophil production is dramatically increased during infection, when 
they rapidly migrate to infected tissues, monocytes (as immature macrophages are known), 
circulate in the blood, and migrate into tissues, becoming macrophages, on a regular basis. 
Although macrophages are phagocytic, they have important roles in the production of 
cytokines and chemokines that modify neutrophil recruitment, adhesion and chemotaxis130. 
Studies into hRSV disease have shown macrophages to secrete a variety of cytokines, 
including IL-1β, IL-6, IL-8, IL-10, IL-12 and TNF-α132.  Surfactant proteins A and D are thought 
to be important in the regulation of alveolar macrophages, ensuring they are only activated 
in response to infection, avoiding unnecessary activation of the immune system and 
subsequent inflammation. The surfactant proteins bind to the alveolar macrophages when 
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no infection is present, and inhibit their activation. When a pathogen is detected, the 
surfactant proteins bind to the pathogen, no longer inhibiting the macrophage, which will 
then be activated and begin to produce its inflammatory mediators which will alert other 
aspects of the immune system118. Macrophages are also important antigen presenting cells 
(APC’s), which will be discussed further in section 1.2.1.5.  
Natural Killer Cells 
Natural killer (NK) cells are important in the innate response to viral infection. They are 
derived from the same lineage as T-cells in the bone marrow, but do not need to mature in 
the thymus. NK cells recognise cells that have abnormal expression of human leukocyte 
antigen (HLA) class I tissue antigens117. These antigens are present on the surface of cells, 
and function to present peptides from pathogens, in order to alert the immune system. If a 
virus is present inside the cell, the expression of HLA molecules will be altered, and this will 
be recognised by the NK cell. HLA recognition is very important in the adaptive response to 
infection. However, some viruses, instead of altering the HLA molecules, are able to down-
regulate them in order to avoid recognition by the adaptive immune system. In this respect, 
NK cells are very important, as they are able to recognise these cells with low HLA 
expression which are missed by other parts of the immune system130.   
NK cells are able to destroy infected cells in a number of ways. Firstly, they contain perforin, 
and upon contact with an infected cell the perforin is transferred to the NK cell’s surface. 
Perforin forms pores in the infected cell membrane, leading to apoptosis. The second 
mechanism NK cells uses is granzyme, three proteolytic enzymes which enter the infected 
cell and activate caspases (cysteine-dependent aspartate-directed proteases), enzymes 
within the cell which initiate degradation of DNA and therefore induce apoptosis. The third 
mechanism used by NK cells is Fas ligand. Fas ligand is expressed on NK cells when they 
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come into contact with infected cells, and binds to Fas on the infected cell, and again 
induces apoptosis through activation of caspases130.  
As well as causing apoptosis, NK cells, like many of the other effectors of the innate 
immune system, secrete cytokines, specifically large amounts of interferon-gamma (IFN-γ), 
which is important in the activation and recruitment of cells of the adaptive immune 
system130.  
1.2.1.5 Antigen-Presenting Cells 
Macrophages have already been discussed in terms of their role as phagocytes, and it was 
mentioned that a further role of theirs is as antigen presenting cells (APCs). APCs provide a 
vital link between the innate immune response and activation of the adaptive immune 
response. Antigens are presented with major histocompatibility complexes, which enable 
recognition by T-cells, and the subsequent development of a specific response to the 
antigen, as well as the development of immunological memory. 
Dendritic Cells 
Dendritic cells are specialised antigen presenting cells (APCs). They are produced in the 
bone marrow, and are named according to their shape, with long ‘dendritic’ processes 
extending from the cell. Dendritic cells are mobile, and travel to peripheral sites where they 
are more likely to come into contact with antigens. Upon encountering antigens, dendritic 
cells bind the antigen, and then travel back toward lymphoid tissue or organs. The dendritic 
cells present the antigen to T-cells which are specific for that MHC-antigen complex. The T-
cell responses will be discussed in further detail in section 1.2.2.2. In the lung, the processes 
on intraepithelial dendritic cells extend into the airway lumen, and are able to pick up 
antigens that have been trapped by the mucociliary escalator130.  
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1.2.2 Adaptive Response 
The adaptive immune system has two main functions. Firstly, if the innate immune system 
isn’t able to destroy pathogens immediately, an adaptive immune response develops, 
specific for that particular pathogen, enabling complete clearance of the invading organism. 
Secondly, the adaptive immune system is responsible for immunological memory, whereby 
the immune system is able to ‘remember’ a particular pathogen from a prior infection. 
When the same pathogen is subsequently encountered on a later occasion, immunological 
memory allows a very rapid, specific, response to be mounted against the pathogen130. 
The adaptive immune system can be divided into two parts – the humoral response, and 
the cell-mediated response.  
1.2.2.1 Humoral Immunity 
Humoral immunity describes the antibody response. Antibodies are proteins produced by 
B-lymphocytes (B-cells), which use various mechanisms to destroy pathogens. Antibodies 
are particularly useful in the defence against extracellular pathogens, as the antibodies are 
able to bind to the free pathogens, and support the destruction by other mechanisms128.  
B-cells are produced in the bone marrow, and like T-cells, the genes for the receptors are 
randomly formed by recombination of DNA segments during the maturation of the cells128. 
This means that a huge number of receptors are randomly generated, being able to 
recognise a diverse range of pathogens which they may come into contact with119. B-cells 
migrate to peripheral lymphoid tissues where they will meet antigens. A B-cell becomes 
activated when it recognises the specific antigen for which it has receptors. The antigen 
binds to IgM and IgD receptors on the B-cell, and depending on the antigen, may or may 
not require stimulation from a helper T-cell in order to be activated. Once activated the B-
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cell undergoes clonal expansion, with production of the same antigen specific B-cells, with 
differentiation to antibody secreting plasma cells, and memory B-cells128. The proliferation 
and differentiation of B-cells is stimulated by a range of cytokines, produced by other parts 
of the immune system. IL-2, IL-4 and IL-21 produced by helper T-cells, as well as IL-6 
produced by helper T-cells, macrophages and many other cells, are all important in B-cell 
proliferation, and also have roles in determining the differentiation. For example, IL-6 has 
been found to have a role in promoting the differentiation of B-cells into antibody secreting 
plasma cells135, while IL-4 has been found to promote the development of memory B-
cells136. Different immunoglobulins have different effects, and are released at different 
times in the response. IgM is released early in the immune response and is particularly 
good in the defence against bacteria. It has 10 potential binding sites, and is able to attach 
to and cause agglutination of bacteria, as well as activating the complement system and 
opsonising the bacteria for phagocytosis130. Viruses and bacteria promote the release of 
IFN-γ from T-helper cells, which then promotes the differentiation of B-cells into IgG 
secreting plasma cells. IgG also opsonises pathogens for phagocytosis by macrophages128. 
IgD has already been mentioned as a receptor on B-cells, where it has a role in the 
identification of antigens and the activation of the B-cells. IgA was mentioned in the 
previous chapter and is found on mucosal surfaces in the respiratory, gastrointestinal and 
reproductive tracts, as well as in saliva, breast milk and tears. It is thought to be one of the 
earlier defences against pathogens, preventing their movement across mucosal surfaces130. 
An example of antibody responses can be seen with hRSV infection. During initial hRSV 
infection IgM is the first detectable antibody, remaining detectable for 1-2 weeks. IgG then 
increases and declines after a couple of months.  The role of antibodies in hRSV has, 
however, been debated. hRSV most commonly occurs in infants, when maternal hRSV 
antibodies are highest, leading to thoughts that the antibodies may have a role in the 
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pathogenesis of hRSV disease. Conversely, it has also been shown that infants with low 
placental hRSV antibodies are more likely to suffer severe hRSV disease, indicating a 
protective role132.   
1.2.2.2 Cell-mediated Immunity 
Cell-mediated immunity is based on the response by T-lymphocytes (T-cells). Cell-mediated 
immunity, in contrast to humoral immunity which is only effective against extracellular 
pathogens, is effective against intracellular pathogens, which may escape other parts of the 
immune system, as well as pathogens within other immune cells, such as those that have 
been phagocytosed by macrophages as part of the innate immune response128.  
T-cell responses are dependent upon presentation of antigen by major histocompatibility 
complexes (MHCs). MHCs are groups of molecules that are able to recognise and present 
antigens. In humans the MHC is known as the human leukocyte antigen (HLA). The HLA 
genes are found on chromosome 6 and encode the HLA molecules. T-cells are only able to 
recognise foreign antigens when they are presented in a complex with a HLA molecule130. 
Two main classes of HLA molecules are important in the activation of T-cells – class I HLA 
molecules are found on almost all cell types within the body, where as class II HLA 
molecules are found on B-cells, macrophages and dendritic cells. Extracellular antigens are 
phagocytosed by macrophages, the proteins from the antigens are degraded and the 
resulting peptides are picked up by HLA class II molecules. The HLA-antigen complex is then 
displayed on the outside of the cell and is recognised by T-cell receptors on CD4+ T-cells130. 
Intracellular antigens such as proteins from viruses activate T-cells via a different route. 
Within the virus-infected cell, proteasome enzymes are able to degrade the viral proteins, 
providing peptides that are able to form complexes with HLA class I molecules. Again these 
complexes are then displayed on the cell surface, and recognised by T-cell receptors, this 
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time on CD8+ T-cells130. The ‘CD’ part of the T-cell is the ‘cluster of differentiation’ which 
describes the molecules on the surface of the T-cell. The CD molecules are essential for the 
stabilisation of the T-cell receptor and the HLA-antigen complex, as well as for signal 
transduction which is vital for activation of the T-cell, with the CD4 molecules being specific 
for the class II HLA and the CD8 being specific for the class I HLA130.  
T-helper cells 
The CD4+ cells are also known as T-helper cells, and once activated may differentiate into 
either Th1 or Th2 cells, depending on the cytokines present at the time.  
Th1 response 
A Th1 response is stimulated by IL-12, which is released from macrophages after IFN-γ 
stimulation. Th1 cells then release Th1 mediators, including IL-2, IFN-γ and TNF-α. The Th1 
mediators stimulate B-cells, macrophages, neutrophils and CD8+ cells (cytotoxic T-
lymphocytes). The macrophages dramatically increase phagocytic activity and the 
destruction of bacteria and viruses, while the B-cells under Th1 stimulation increase the 
production of IgG, again opsonising the pathogens for phagocytosis130. 
Th2 response 
Without the IL-12 stimulation, and the absence of innate cytokines such as IFN-γ, T-helper 
cells differentiate into Th2 cells, releasing a different array of mediators, particularly IL-4, IL-
5 and IL-13. These mediators stimulate B-cells to produce IgE, which then goes on to 
activate eosinophils and mast cells, characterising a Th2 response, which would be 
characteristic in atopic asthma. IL-13 has a role in mucosal activation, causing mucus 
hypersecretion and increased contractility in the airways137.   
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Cytotoxic T-cells 
The CD8+ cells are also known as cytotoxic T-cells, as they are directly able to destroy 
pathogens. As class I MHCs are found on almost all cell types within the body, CD8+ cells do 
not immediately react to a class I MHC-antigen complex. CD8+ cells are activated either by 
a class I MHC-antigen complex presented by a professional APC, or by a class I MHC-antigen 
complex on a non-professional APC, along with a secondary signal in the form of cytokines 
released by a an activated CD4+ T-helper cell. Once activated cytoyoxic T-cells use the same 
mechanisms as NK cells to destroy pathogens. Perforin is used to form pores in the cell 
membrane causing cell lysis, and granzyme and fas ligand are used to induce apoptosis130. 
Th17 Response 
More recently, a new T-cell lineage has been described – Th-17 cells. They are a group of 
CD4+ T-cells that produce so-called Th-17 cytokines including IL-17A, IL-17F, IL-26 and IL-
22138. Th-17 cytokines were initially associated with autoimmune disease, but have more 
recently been implicated in the host immune response to infection. They are strong 
mediators of inflammation, and abnormalities in the regulation of this inflammation has 
been implicated in autoimmune disease138.   IL-17A is produced by Th-17 cells, as well as 
CD8+ T-cells, NK-cells and neutrophils137. 
Differentiation of CD4+ T-cells into Th17 cells is thought to result from the effects of TGF-β, 
IL-1β, IL-6, IL-21 and IL-23. The production of IL-17 is dependent on IL-6 and IL-23, released 
from macrophages and dendritic cells. Regulatory mechanisms are in place with neutrophils 
that are apoptotic following pathogen destruction inhibiting IL-23 production by dendritic 
cells, and therefore suppressing the differentiation of CD4+ cells into Th17 cells.    
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IL-17A and IL-17F exert their pro-inflammatory actions via a number of mediators. They 
induce G-CSF and GM-CSF expression, increasing the production of neutrophils and 
monocytes. They also stimulate neutrophil mobilisation, recruitment and activation, as well 
as stimulating fibroblasts to release IL-6 and IL-8137. IL-22 is also strongly pro-inflammatory, 
working synergistically with IL-17A and IL-17F, but also enhancing the expression of 
antimicrobial peptides such as the defensins138.  IL-17E and IL-25 are somewhat different, 
and have been associated with a Th-2 response, with IL-17E being involved in eosinophil 
recruitment and the expression of Th-2 cytokines, and IL-25 stimulating eosinophils and 
basophils137.   
Studies have found Th17 responses to be critical in the defence against extracellular 
bacteria, as well as having a role in the defence against intracellular pathogens138. One of 
the first pathogens investigated was Klebsiella pneumoniae, a Gram negative bacterium 
that is often associated with hospital acquired pneumonia. IL-17 deficient mice were 
infected with Klebsiella pneumoniae, and found to have deficient neutrophil responses, 
increased bacteraemia and increased mortality when compared to controls. The lack of IL-
17 was found to drastically reduce levels of certain chemokines as well as G-CSF, which led 
to the deficient neutrophil response138. IL-17 has also been shown to be important in the 
defence against Mpp,   via an IL-23 dependant pathway. Wu et al used a murine model and 
reported increased IL-23 as early as four hours after Mpp infection, along with a 
subsequent increase in IL-17 in BAL. Upon blocking IL-23, IL-17 protein and mRNA 
expression was significantly reduced, along with neutrophil recruitment and neutrophil 
activity, which led to decreased clearance of the infection139.  
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Th17 cytokines, along with all other cytokines and chemokines, are vital mediators of 
inflammation, and have critical roles in the co-ordination of the innate and adaptive 
immune responses to infection.  
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1.3 Aims of this study 
The main objectives of this study were to characterise the viral and atypical bacterial causes 
of ARI in a clinically and demographically well-defined group of children under the age of 
five, and to investigate any associations between pathogens and particular demographics 
or clinical manifestations such as clinical diagnosis or severity of disease. We also aimed to 
characterise cytokine profiles in children with varying severities of disease, and with disease 
caused by different pathogens, to investigate the following hypotheses: a) different 
severities of hRSV disease are characterised by different host immune responses; and b) 
host immune responses in infection vary depending on infecting pathogen.   
In order to address these aims we performed an observational, cross-sectional study. 
Nasopharyngeal aspirates, along with clinical and demographic information, were collected 
from children under the age of five with signs and symptoms of ARI. The NPAs were 
analysed for a range of viral and atypical bacterial pathogens, and the results were used to 
select samples for cytokine analysis. The study has been organised into the following 
chapters: 
- Demographic and clinical information 
- PCR results 
- Cytokine analysis 
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2 Methodology 
This chapter outlines the general methods used throughout the study. To avoid repetition 
details of all reagents and equipment mentioned in this chapter can be found in appendices 
1 and 2, respectively.    
2.1 Study Design 
The study was a prospective, observational, cross-sectional study carried out over a period 
of twelve months at the IMIP Children’s hospital, Recife, Brazil. The study was approved by 
the ethics committee at IMIP and the National Research Ethics Office of Brazil. 
2.2 Recruitment 
Between April 2008 and March 2009, children under the age of five, presenting with acute 
respiratory infection (ARI) to the IMIP children’s hospital, Recife, Brazil, were enrolled in the 
study. All children less than five years of age presenting with upper and/or lower 
respiratory tract manifestations of ARI of less than seven days duration were eligible for 
inclusion. Written parental consent to take part in the study was obtained for each child. A 
total of 407 children were enrolled in the study, with 68.6% being under 12 months of age. 
2.3 Demographic and Clinical Information 
Demographics 
The study was conducted in the IMIP Children’s Hospital, Recife, Brazil. Recife is the capital 
city of the State of Pernambuco, and is situated on the North East coast of Brazil (Figure 1). 
The metropolitan region of Recife has a population of approximately 3.7 million, with the 
city itself having approximately 1.5 million inhabitants, making it the fourth largest 
metropolitan region and ninth largest city in Brazil. Recife’s tropical climate sees average 
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temperatures between 22oC and 31oC. The coolest temperatures and maximum rainfall are 
experienced within Brazil’s winter months, between June and August.   
Recife has the highest proportion of favela residents, and the third highest number overall 
in the country, after only Sao Paulo and Rio de Janeiro, with an estimated 800,000 residents 
living in the shanty towns140. The majority of favelas in Recife have been around since the 
1970’s when a large number of people moved from rural areas into the city in search of 
work. The favelas are illegal settlements on the edge of the city, with high crime rates and 
poor standards of living. Many people living in favelas do not finish basic education, and 
although college and university attendance is free in Brazil, entrance exams have to be 
passed, which are impossible if secondary education has not been attained. The living 
conditions are often crowded, with very basic electricity supplies, and a lack of clean water 
(Figure 2).  
Upon enrolment into the study the parent of each child was asked to complete a 
questionnaire containing 95 questions detailing the child’s birth history; past medical 
history; social history and family history, as detailed in Appendix 3.  
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Figure 1: Map detailing the location of Recife 
 
 
 
Figure 2: Photograph of one of Recife's favelas 
 
 
 
 
  
Recife 
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Clinical Information 
Clinical details such as the child’s admission weight, heart rate, respiratory rate, 
temperature, and the presence or absence of symptoms such as chest in-drawing, cyanosis, 
cough and wheeze were recorded. The discharge diagnosis, as described by the attending 
physician, was recorded along with the severity of disease. Diagnoses were made upon 
discharge from hospital by clinicians who were not otherwise involved in the study, 
according to standard clinical criteria. Bronchiolitis was diagnosed in children under 18 
months of age, who presented with a history of upper respiratory symptoms preceding 
lower respiratory symptoms of wheeze, tachypnoea and signs of respiratory distress. 
Pneumonia was diagnosed in children with fever, tachypnoea and respiratory distress, 
along with focal or diffuse crackles or decreased vesicular sounds on auscultation. A 
diagnosis of episodic viral wheeze (EVW)/asthma was made in children with discreet 
episodes of wheeze, often in association with presumed viral upper respiratory tract 
infection. Upper respiratory tract infection was diagnosed in children with symptoms such 
as coryza, earache, sore throat and stridor. Radiographs were available to assist diagnosis in 
some cases but not all.  
Severity of disease was categorised as follows: very mild – upper respiratory signs only; mild 
– lower respiratory tract signs but no need for hospital admission; moderate – lower 
respiratory tract signs, with the need for hospital admission requiring nasogastric or IV 
fluids, but no oxygen; and severe – lower respiratory tract signs and the need for hospital 
admission and  oxygen or ventilation.  All children admitted to hospital were followed daily, 
with length of stay, outcome of illness and any further complications being recorded. 
Appendix 3 summarises the points covered by the questionnaire.  
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2.4 Sample collection & processing 
2.4.1 Nasopharyngeal Aspirate collection 
Nasopharyngeal aspirate (NPA) samples were collected from recruited children in A&E, on 
the ward or on the paediatric intensive care unit (PICU), to obtain samples of secretions 
from the upper respiratory tract.   
NPAs were taken according to a previously described, standardised protocol141.  
All NPAs were collected by one research assistant (Figure 3) to minimise measurement bias. 
According to the study’s protocol, all samples were processed within two hours, with 
dilution in 3mls of normal saline (0.9% NaCl in H2O). The cell counts were calculated and the 
samples were then centrifuged at 500g for 10 minutes at 4oC. The samples were split into 
the cell pellet and supernatant. The cell pellet was resuspended in a solution of 2-
mercaptoethanol and RNA lysis buffer. The supernatant was split into two aliquots. All 
samples were stored at -70oC.  The samples were all transported in dry ice to the UK for 
analysis.  
2.4.2 RNA Extraction 
DNA and RNA were co-extracted from samples using the QIA symphony Virus/Bacteria Mini 
Kit (Pathogen Complex 200 protocol), according to manufacturer’s instructions, using 300µl 
of each sample, added to 100µl animal tissue lyssis (ATL) lysis buffer. The RNA samples 
were stored at -70oC until further analysis. 
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A)     B) 
 
Figure 3: Nasopharyngeal aspirate collection 
A) All NPAs were collected by one research assistant. B) NPA equipment  
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2.5 PCR Analysis 
2.5.1 Introduction to PCR 
The polymerase chain reaction (PCR) is a technique that allows the amplification of a 
specific region of DNA in vitro142.  
DNA consists of a double helix, made up of two strands of DNA running antiparallel to each 
other, with hydrogen bonds connecting complimentary bases – guanine (G) and cytosine 
(C), and adenine (A) and thymine (T)142.  
The first step in PCR is denaturation of the double helix. The DNA is heated to 94-95oC in 
order to break the hydrogen bonds between the base pairs and separate the strands of 
DNA, providing two single stranded DNA templates for amplification. The temperature is 
then lowered according to the primers being used143.  
Primers are short sequences of DNA, usually around 20 nucleotides long. Primers 
complimentary to particular regions of the template sequence of DNA are added, to which 
they will anneal (form hydrogen bonds), giving a starting and end point for DNA synthesis. 
DNA polymerase will then catalyse DNA synthesis between the primers, adding the correct 
deoxynucleotides, complimentary to those on the template DNA to which they can anneal, 
subsequently forming a new double stranded structure, identical to the original143.  The 
primers essentially define the region of DNA which is to be copied, and subsequently 
amplified.  
Following this first replication of the initial DNA templates, two copies of the original DNA 
are produced, each containing one strand of original DNA (the template), and the new 
strand of DNA. The new double stranded molecules are once again heated to 94-95oC, 
leading to denaturation, now providing four new templates for replication143.   
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This cycle of denaturation and annealing is repeated between 20-40 times, each time 
doubling the number of copies of the DNA sequence, with the potential to provide millions 
of copies from a very small number of template DNA molecules143. 
The newly synthesised DNA can then be analysed, most commonly by gel electrophoresis, 
which will separate the DNA molecules in order of size. The newly synthesised DNA can 
then be compared to known DNA sequences, therefore allowing identification143. 
Multiplex PCR 
Multiplex PCR uses multiple pairs of primers in the same reaction to amplify multiple 
sequences of DNA. This allows the detection and identification of multiple viruses within 
one reaction. Prior to the development of this, in order to identify more than one virus, 
each sample had to be prepared and PCR performed for each individual virus. Multiplex 
PCR has major advantages in terms of decreased cost and preparation time in comparison 
to original methods144.   
Real –Time PCR 
Real-time PCR is another variant of PCR which includes an extra step in which the PCR 
products are analysed in the same reaction. Instead of gel electrophoresis to detect specific 
DNA, real-time PCR uses a specific DNA binding dye or primer which fluoresces when bound 
to the product, which is then detected143. The reaction can either be quantitative, in which 
the fluorescent signal is quantified, and can be compared throughout the cycle, or it can be 
qualitative, giving a ‘positive’ or ‘negative’ response to a sample143.  Real-time PCR makes 
interpretation of results very simple, and eliminates the need for gel electrophoresis which 
can be time-consuming.  
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2.5.2 PCR Methods 
Five separate multiplex PCR assays were used to detect 17 different respiratory pathogens. 
The first assay comprised of influenza A (flu A), influenza B (flu B), human 
metapneumovirus (hMPV) and human respiratory syncytial virus (hRSV), as well as primers 
and probes specific for novel H1N1 influenza. The second comprised of coronavirus (CoV) 
OC43, NL63, 229E and HKU 1.  The third included parainfluenza virus (PIV) types 1, 2, 3 and 
4 and hRV. The fourth included adenovirus (AdV), Mycoplasma pneumoniae (Mpp) and 
Chlamydia pneumoniae (Cpp); and the fifth included human bocavirus (hBoV).  
Multiplex reverse-transcription PCR was performed for the detection of RSV, hMPV, Flu A 
and B, PIV1-4 and hRV using the Invitrogen Superscript III Platinum One-Step Quantitative 
RT-PCR System as described previously145. Additional primer-probe sets were used for the 
detection of COVs (OC43, NL63, 229E and HKU1), also using the Invitrogen Superscript III 
Platinum One-Step Quantitative RT-PCR System as described by Gunson et al146. The RNA 
was denatured at 95oC for one minute prior to mastermix addition on ice. 5µl nucleic acid 
was added to 20µl master mix.  PCRs with DNA targets utilized 10µl nucleic acid to detect 
AdV/Cpp/Mpp and hBoV using the Roche LC480 Probes Master Kit and Qiagen Quantitect 
Probe PCR Kit respectively147 148. Cycling conditions were as described previously145, except 
for removal of the 50oC hold for reverse transcription in the AdV/Cpp/Mpp and hBoV 
assays, and the 95oC enzyme activation hold was extended to five minutes for the 
AdV/Cpp/Mpp assay, and to 15 minutes for the hBoV assay (Appendix 4). All primers and 
probes are listed in Appendix 5. All assays were performed in 96-well plates, in the 
LightCycler® 480 Real-Time PCR System. 
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2.6 Cytokine analysis 
2.6.1 Protein Assay 
Sample protein concentrations were measured to normalize cytokine concentrations by 
dilution and enable comparison across groups. 
A protein assay was performed using the QuantiPro BCA Assay Kit to determine the protein 
concentration of each sample. 
Protein concentrations were calculated from measured absorbances following interpolation 
to a bovine serum albumin (BSA) standard curve. The standard curve consisted of seven 
serial two-fold dilutions with a top standard of 30µg/ml.  Samples were centrifuged at 
8000RPM to pellet cellular debris. The samples were then diluted 1:14 with PBS, adding 
20µl sample to 280µl PBS in each well. The reagents were made up by adding 75µl reagent 
A, 75µl reagent B and 3µl reagent C to each well. The plate was incubated for one hour at 
60oC before being read at 540nm on the ELx800 absorbance microplate reader. 
2.6.2 Background – Bio-Plex technology 
The Bio-plex system is a relatively new development in the detection of cytokines. The 
technology has developed from the enzyme-linked immunosorbent assay (ELISA), where 
the principle is based upon coating a plate with the antigen – the cytokine or biomarker in 
question – either directly or with the use of a capture antibody. The antigen is then bound 
by an added detection antibody. An enzyme is then added which will bind to the antigen-
antibody complex, with levels of enzyme activity being determined by the addition of a 
colorimetric substrate solution. This colour change can then be quantified using a 
photometer149.   
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Bio-plex technology uses similar principles, but the capture molecules are bound to 
polystyrene microbeads added to a microplate, instead of just the floor of the plate. The 
antigen, or substance containing the antigen, is then added, and binds to the capture 
molecules. A detection antibody, labeled with a fluorescent marker, is then added, which 
will bind to the antigen-antibody complex. The microplate is then read using the Bio-Plex 
array reader, which draws up the beads from each well in a single line, and each bead is 
then passed through two lasers which excite the beads and fluorescent markers, generating 
a fluorescent signal. The strength of the signal is determined by the amount of the captured 
antigen, allowing quantification. The biggest advantage of this technique is that many 
different colour coded beads can be added to the same assay, detecting multiple antigens 
simultaneously. This multiplex method has been developed to enable the detection of up to 
100 different antigens at once. In this study we have used the Bio-Plex system along with an 
8-plex kit, to which we added IL-17 beads in order to detect the following nine cytokines of 
interest: IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-γ, TNF-α and IL-17. 
2.6.3 Cytokine Analysis 
Standard Preparation 
One vial of premixed lyophilized standard was reconstituted with 500µl standard diluent. 
An eight point standard curve was constructed using 1:4 serial dilutions in standard diluent.  
Sample preparation 
Nasopharyngeal aspirate supernatant samples were centrifuged at 8000RPM for five 
minutes at 4oC. A 1:6 dilution of each sample was used adding 25µl sample to 125µl human 
serum diluent.  
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Bead Preparation 
Each set of coupled magnetic beads (8-plex kit containing IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, 
IFN-γ and GM-CSF; plus a separate IL-17 kit) were quick-spun, then resuspended before 
adding to 4600µl assay buffer. 
Detection Antibody Preparation 
Each detection antibody (10x) was vortexed for 10-15 seconds, and centrifuged for 30 
seconds before being added to 2400µl detection antibody diluent to make a 1x dilution. 
Streptavidin-PE Preparation 
Streptavidin-PE (100X) was prepared by vortexing for 1-3 seconds, and centrifuging for 10-
15 seconds, before adding to 5940µl assay buffer to make a 1x dilution. 
Assay Procedure 
The Bio-Plex Pro flat bottom plate was pre-wet with 100µl assay buffer per well. Excess 
buffer was removed from the plate using a vacuum manifold calibrated at 1-3”Hg. The 
prepared coupled beads were added to the plate, 50µl per well. The plate was washed 
twice by adding 100µl wash buffer, with excess liquid being removed using the vacuum 
manifold as before. Prepared standards and samples were added to the plate (50µl per 
well), before incubating for 30 seconds at 1100RPM, then for a further 30 minutes at 
300RPM in the dark. After incubation the plate was washed x3 as before. Detection 
antibody was added to each well (25µl) before incubating as before. The plate was washed 
x3 before adding 25µl streptavidin-PE to each well, before incubating at 1100RPM for 30 
seconds, followed by 10 minutes at 300RPM in the dark. The plate was washed x3 before 
adding 125µl assay buffer per well to resuspend the beads. The plate was shaken at 
1100RPM for 30 seconds prior to reading using the Bio-Plex Array 200 system. 
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2.7 Statistical Analysis 
All data was recorded on a database in Microsoft Excel 2007. All statistical analysis was 
performed on SPSS 18.0.1 statistical package (SPSS Inc, Chicago).  
The Kolmogorov-Smirnov test 
The Kolmogorov-Smirnov test was used to determine whether specific variables were 
normally distributed, in order to guide statistical testing. When a significant value was 
found, indicating that a variable was not normally distributed, non-parametric tests were 
employed for further testing.  
Normally distributed data 
Normally distributed data were expressed as mean with standard deviation (SD). In order to 
compare differences between two normally distributed groups, the students t-test was 
used.  
Non-parametric data 
Non-parametric data were expressed as median with the range. In order to investigate 
differences between two non-parametric groups, a Mann-Whitney U test was used. If there 
were multiple non-parametric groups for comparison, a Kruskal-Wallis test was used, and if 
differences were detected, a Mann-Whitney U test was performed to locate the groups 
within which these differences existed.  
Categorical Variables 
In order to compare differences between categorical variables, a Chi-square test was used. 
Bonferroni Correction 
When performing multiple comparisons, the likelihood of finding a significant difference 
between variables by chance (a type 1 error) is increased. A Bonferroni correction was used 
when performing multiple comparisons to decrease the likelihood of this. 
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Graphs 
Bar graphs and box and whisker plots have been used to graphically display data. In box and 
whisker plots the median is marked as a line within the box, the edges of the box indicate 
the interquartile range, and the ‘whiskers’ indicate the overall range of the data.  
Graphs were created using Microsoft Excel 2007 (chapter 3 and chapter 4), and SPSS 18.0.1 
(chapter 5). 
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3 Demographic and Clinical Characteristics 
3.1 Introduction 
Although a number of studies have investigated the epidemiology of acute respiratory 
infection (ARI) in developing countries, none have detailed the demographic or clinical 
characteristics of the population studied, or addressed the impact these factors may have 
on results.  It is important to analyse and document demographic and clinical information, 
not only because it enables findings of a study to be put into context with other studies, but 
to put the results themselves into context and allow them to be used in clinical practice. In 
the case of ARI this is particularly true, as demographic and clinical factors, such as 
overcrowding, smoking, prematurity and low birth weight, have all been shown to be risk 
factors for ARI. Knowledge of clinical information allows potential risk factors and causes to 
be linked to clinical conditions, and helps identify confounders which may affect the 
accuracy and reliability of results.  
The aims of this chapter are: 
1. To define the demographics of the study population. 
2. To outline the background and presenting clinical information of the study 
population. 
 
3.2 Methodology 
Clinical and demographic information was obtained using a detailed questionnaire as 
described in section 2.3.  
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3.3 Results 
A total of 407 children and infants under the age of five were enrolled into the study over a 
12 month period from April 2008 to March 2009. Table 2 summarises the demographic and 
clinical characteristics of the study population.  
3.3.1 Demographics 
The study population comprised of 171 girls (42.0%) and 236 boys (58.0%).  The median age 
of study participant was 8.0 months (range 0-57), with 68.6% of participants being under 12 
months old (Figure 4). 
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Table 2 : Summary of clinical and demographic characteristics of study population
Characteristic Value 
 Male (%) 
 Female (%) 
 Median age, months 
 Age range, months 
236 (58.0) 
171 (42.0) 
8 
0-57 
Socio-economic factors: 
 Median (range) primary household income 
 Mean (SD) number of years parents studied: 
o Mother  
o Father 
 Number (%) of parents who attended higher 
education: 
o Mother 
o Father 
 
$R 415.00 (30-1800)                                                      
 
7.63 (3.065) 
7.54 (3.197) 
 
 
3 (0.8) 
5 (1.3) 
Living Conditions: 
 Median (range) number living in accommodation 
 Median (range) number sleeping in same bedroom 
as child 
 Number (%) of children exposed to smoking at 
home 
 
4 (1-17) 
 
3 (1-10) 
 
174 (42.8) 
Birth History: 
 Mean (SD) birth weight, grammes 
 Gestation <37 weeks (%) 
 Gestation <32 weeks (%) 
 Number of children breastfed (%) 
 
3420.88 (1568.64) 
78 (19.2) 
9 (2.2) 
374 (91.9) 
Past Medical History: 
 Co-morbidities (%) 
 Asthma Diagnosis (%) 
 Admission to hospital in last 30 days (%) 
 
19 (4.7) 
37 (9.1) 
49 (12.0) 
Presenting Features: 
 Cough (%)  
 Wheeze (%) 
 Coryza (%) 
 Fever (%) 
 
399 (98) 
322 (79.1) 
268 (65.8) 
296 (72.7) 
Severity 
 Very mild (%) 
 Mild (%) 
 Moderate (%) 
 Severe (%) 
 
23 (5.7) 
173 (42.5) 
169 (41.5) 
42 (10.3) 
Diagnosis 
 Bronchiolitis (%) 
 Episodic Viral Wheeze/Asthma (%) 
 Pneumonia (%) 
 Upper respiratory tract infection (%) 
 Other (%) 
 
211 (51.8) 
55 (13.5) 
109 (26.8) 
23 (5.7) 
9 (2.2) 
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Figure 4: Distribution of age in study population.  
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Socio-economic Status 
The questionnaire included several questions relating to the living conditions and socio-
economic status of each participant and their family. The first indicator that was addressed 
was household income. The median (range) household monthly income for the study 
participants was found to be R$415.00 (30-1800) (Brazilian Reais). This equates to 
approximately US$235.99. Of the study participants, 85.9% had monthly incomes below 
R$800 (the overall mean Brazilian monthly income150). A total of 48 (11.8%) of participants 
lived in accommodation with no water supply, and 56 (13.8%) of participants lived in 
households that did not use any form of water purification.  All participants were asked 
about the power supply to their home, and 404 (99.3%) study participants were found to 
have some form of electricity supply to their accommodation.  
The questionnaire also documented the number of residents per household and in 
particular the number of people sharing a bedroom with the study participant. The median 
number of people living in the same household as the child was 4, with a range from one 
other person, to 17 others. The median (range) number of people sharing a bedroom with 
the study participant was 3 (0-10), with only 28 (6.9%) having their own room, and 105 
(25.8%) having at least four in the same room. The median number of siblings of our study 
participants was 2, with a range from zero to 10.  
One further parameter that may indicate socio-economic status is the number of years of 
education the parents of each participant received151. The mean (SD) number of years the 
mother studied for was found to be 7.63 (3.065), with 56.5% having studied for less than 
Brazil’s ‘mandatory’ nine years. The mean (SD) number of years the father studied for was 
found to be similar - 7.54 (3.197) – with 55.5% having studied for less than nine years. Out 
of the whole study population, only 5 (1.3%) fathers and 3 (0.8%) mothers had attended 
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college or university (this data was deduced from the number having studied for more than 
11 years).  
Smoking 
Out of the 407 study participants, 174 (42.8%) came from households in which at least one 
member of the household smoked.   
Birth History 
The questionnaire included questions on birth weight, gestation, breastfeeding and 
weaning. The median (range) birth weight for the study population was 3120.00g (970-
3965g). Overall, 56 (13.8%) participants had a birth weight of less that 2500g, and 78 
(19.2%) study participants were born prematurely (less than 37 weeks gestation), although 
only 9 (2.2%) were born at less than 32 weeks gestation. Out of the total 407 children 
enrolled onto the study, 374 (91.9%) had been, or were currently being, breastfed.  
Vaccinations 
The questionnaire included questions regarding whether or not the child had been 
vaccinated against tuberculosis (TB), diphtheria, Haemophilus Influenzae type b (Hib), 
Streptococcus pneumoniae (S. pneumoniae), and influenza (flu). Only four children (1.0%) 
had not had the BCG vaccine (against TB). However, 67 children (13.4%) had not received 
the diphtheria vaccine, and 73 children (14.6%) had not received the Hib vaccine. A total of 
331 children (81.3%) had not been given the pneumococcal vaccine, while 334 (82.1%) had 
not had the influenza vaccine.  
Past medical history and co-morbidities 
Specific questions were asked regarding any co-morbidities the child may have, any recent 
hospital admissions or any previous respiratory symptoms, and specifically if the child had 
been diagnosed with asthma, or had ever had tuberculosis. Overall, 49 children (12.0%) had 
been admitted to hospital within the last 30 days. Out of the total 407 children, 37 (9.1%) 
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had previously been diagnosed with asthma by a doctor, and no study participants had ever 
been diagnosed with TB.  A total of 52 patients (12.8%) had been admitted to hospital with 
pneumonia in the past, 238 children (58.5%) had previously had an episode of wheezing, 
and 21 (5.2%) had been diagnosed with allergic rhinitis by a doctor. 
Out of the 407 study participants, 19 (4.7%) had a co-morbidity. The most common type of 
co-morbidity was heart disease in 7 patients, followed by neurological (4 patients) and 
genetic (3 patients) abnormalities (Table 3). 
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Table 3: Table detailing the presence of co-morbidities in study population 
 
Co-morbidity Type Frequency 
Heart disease 7 
Chronic Lung disease 1 
Genetic abnormality 3 
Neurological  4 
Genetic/Immunodeficiency 1 
Diaphragmatic eventration 1 
Cardiac/neurological 1 
Cow’s milk protein allergy 1 
72 
 
3.3.2 Clinical Information 
Presenting features 
The most common symptoms present on admission were cough in 399 children (98%), 
wheezing in 322 (79.1%), coryza in 268 (65.8%) and fever in 296 (72.7%). Chest indrawing 
was observed in 48 children (11.8%), while 22 (5.4%) had oxygen saturations below 90% on 
admission. Episodes of apnoea were reported in 19 children (4.7%), and one child out of the 
407 was found to be cyanotic on clinical examination (0.2%).  
Severity 
The severity of disease of each patient, as described in section 2.3, was recorded (Figure 5). 
The most common severity observed was mild disease (173 participants; 42.5%), followed 
by moderate (169 participants; 41.5%), then severe (42 participants; 10.3%), and finally very 
mild (23 participants; 5.7%). The low numbers of children with very mild disease reflects the 
fact that recruitment took place in a hospital, meaning that children with ARI attending 
general practitioners or nurse led clinics, or not consulting at all, were not included in the 
study. Just over half (212, 52.1%) the study participants were admitted to hospital with the 
ARI, while the other 195 were seen and discharged on the same day. Of the 407 children 
enrolled in the study, only two required admission to the intensive care unit. There were 
three deaths (0.7%) in the study population during the study period.  
Clinical Manifestations 
The diagnosis of each child was recorded upon discharge from hospital (Figure 6). 
Bronchiolitis, pneumonia, episodic viral wheeze (EVW)/asthma and upper respiratory tract 
infection (URTI) made up 97.8% of the diagnoses. Bronchiolitis was the most common, 
affecting 211 children (51.8%), followed by pneumonia, affecting 109 children (26.8%), then 
EVW/asthma, affecting 55 children (13.5%) and finally URTI, affecting 23 children (5.7%). 
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The other 2.2% (9 participants) were diagnosed with other conditions, including laryngitis, 
laryngotracheobronchitis and pneumonia with pleural effusion.  
Over three-quarters of children diagnosed with pneumonia required admission to hospital 
(84/109; 77.1%), compared to 49.8% of those with bronchiolitis (105/211) and 23.6% of 
those with EVW/asthma (13/55). 
Demographic effects on severity  
The following demographic parameters were investigated with regard to severity of 
disease: household income; breastfeeding; birth weight; parental smoking and number of 
siblings. Following statistical analysis using a chi-square test, the only variable found to 
have a significant relationship with severity was birth weight. Children in the study with a 
birth weight under 2500g were found to be more likely to have moderate or severe disease 
than mild disease (p=0.009 and p=0.005, respectively). No other variables were found to 
significantly affect severity of disease.  
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Figure 5: Distribution of severity of disease in study population.  
Very mild – upper respiratory tract signs and symptoms only; mild – lower respiratory tract signs and 
symptoms but not requiring hospital admission; moderate – lower respiratory tract signs and 
symptoms requiring hospital admission; severe – lower respiratory tract signs and symptoms 
requiring hospital admission and oxygen or ventilation. 
 
Figure 6: Clinical diagnoses recorded in study population.  
0
20
40
60
80
100
120
140
160
180
200
Very mild Mild Moderate Severe
Fr
e
q
u
e
n
cy
Severity
0
50
100
150
200
250
URTI Bronchiolitis Pneumonia EVW/asthma Other
Fr
e
q
u
e
n
cy
Diagnosis
75 
 
3.4 Discussion 
This chapter describes detailed demographic and clinical characteristics of the study 
population. Several factors suggest that this study population has an overall lower socio-
economic status than that of Brazil as a whole.  
The median monthly household income was found to be R$415 (US$235.99). This is in 
comparison to Brazil’s overall mean monthly household income of R$805 (US$451)150. The 
number of people per household, (median 4, with up to 17 in one case), and the number of 
people sharing a bedroom with the study participant (25.8% had at least 4 in the bedroom), 
show a degree of overcrowding, or at least cramped living conditions. Poor living 
conditions, and especially overcrowding, are factors that will affect the spread of disease, 
and more specifically respiratory infections16 20 22 23. The low socioeconomic status of the 
study population, when compared to the whole population, can be explained, at least in 
part, by the structure of the healthcare system in Brazil. Brazil has a large private healthcare 
sector (52.1% of total health expenditure152). Such a large private healthcare sector will 
explain the discrepancies in mean income and living conditions of our study participants, 
with all recruitment to this study being from the IMIP Children’s Hospital, a government run 
hospital providing free healthcare for those that need it.  
Low parental literacy levels have been reported as a risk factor for ARI in children151. Pre-
school education in Brazil for children under the age of 6 is optional. The only compulsory 
education or ‘Fundamental Education’ as it is known in Brazil, is given between the ages of 
6 and 14, consisting of nine ‘years’ of learning. Secondary education is free to all, but is 
optional, and the ‘Fundamental Education’ must have been completed in order for 
someone to attend. Secondary education lasts for three years, and is mandatory for anyone 
wanting to pursue Higher Education. Higher Education is free at public universities, 
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although a competitive entrance exam must be passed in order to secure a place. The fact 
that over 50% of our study population’s parents attended education for less than the 
mandatory nine years, with only 35.7% having attending secondary education, and a very 
small minority attending college or university (0.8-1.3%), highlights the fact that this 
population is not representative of the whole of Brazil, but represents a population with a 
lower socio-economic status, many of whom probably come from the poorest families in 
the city, living in favelas with poor living conditions.  
An association between passive smoking and respiratory illness in children has been long 
established, with studies showing an increased risk of severe respiratory illness28 29. In our 
study population, 42.8% of children came from homes in which at least one person was a 
smoker. This rate of smoking is higher than the Brazilian national average, where in the year 
2000, 35.4% of males and 26.9% of females were smokers, with both figures falling (males 
from 38.2% and females from 29.3% in 1995)153. This is also in contrast to the United States 
in which 23.9% of males, and 18.1% of females are smokers. We may speculate that the 
high percentage of our study population coming from homes in which there are smokers 
may be due to our study population having a lower socio-economic status than the overall 
Brazilian population. Many studies have shown that smoking rates are higher in lower 
socio-economic groups25-27. Secondly, several studies have found relationships between 
exposure to cigarette smoke and both increased likelihood of ARI in young children, and 
increased severity and likelihood of admission for ARI28 29, meaning our high proportion of 
children from homes with smokers could explained because the exposure to smoke is 
putting them at a higher risk of admission. Finally, overcrowding will increase the likelihood 
of a child living in a household with a smoking adult. 
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The study population contained 56 children (13.8%) who had a birth weight under 2500g, 
and 19 children (4.7%) who had a co-morbidity. These statistics are lower than would be 
expected, as prematurity, along with cardiac and respiratory problems are all risk factors 
specifically for hRSV disease and are all associated with increased severity154. It is 
encouraging that 91.9% of the study population had been or were still currently being 
breastfed, as it has been found that infants age 0-5 months who have not been breastfed 
have a five-fold increased risk of death from pneumonia compared to those who had 
been155. These factors indicates that our study population is a generally otherwise healthy 
population, with a low co-morbidity rate and high levels of breastfeeding. 
No children within the study population had ever had TB, which reflects the high uptake of 
the BCG vaccination. It is more difficult to assess the other vaccinations, because unlike the 
BCG (which the Brazilian Ministry of Health recommend is given in one dose at birth), 
diphtheria and Haemophilus influenzae type b (Hib) vaccines should be given at 2, 4 and 6 
months156. As 39.1% of our study population is under 6 months of age, it is difficult to 
assess whether or not they should have completed the vaccinations, and with 13.4% and 
14.6% having not received the diphtheria and Hib vaccines, respectively, this could be 
correct due to the patients’ age, giving an overall high uptake of the vaccines. At the time of 
data collection the pneumococcal conjugate vaccine, and the influenza vaccine were not 
routinely recommended by the Brazilian Ministry of health, which explains why 81.3% and 
82.1%, respectively, had not received the vaccines156. 
Bronchiolitis is the most common diagnosis in the study population. This reflects the age 
range of the population studied, with bronchiolitis being the most common cause of 
hospital admission in children under the age of one in winter months. There were relatively 
few children in the study population with URTI (23, 5.7%), reflecting the fact that although 
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URTI is very common, in the majority of cases it manifests as the common cold, which is not 
usually severe enough to warrant attendance at the emergency department, or hospital 
admission.  
The classification of severity of disease in the study population has shown a spectrum from 
very mild disease with upper respiratory tract signs and symptoms only, to severe disease 
with children needing oxygen, and in some cases mechanical ventilation. Although this wide 
range of severities has been used, a limitation of this severity classification lies within the 
study design. As it is a cross-sectional study, it only investigates one point in time. Children 
with very mild or mild disease, who weren’t admitted to hospital, were classified according 
to severity at the point of attendance at the emergency department. As children would 
have attended at different time points in the course of their illness, the severity may have 
changed following discharge. For example a child who initially only had upper respiratory 
tract signs and symptoms may have developed lower respiratory tract signs and symptoms 
once they had left hospital, which would have been changed their severity from very mild 
to mild, but as they had already left hospital they would have been included in the study as 
a ‘very mild’ patient. 
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4 PCR Results 
4.1 Introduction 
The correct identification of the causative agent in acute respiratory infection (ARI) is 
important as it may help determine management. A previous study of children with viral 
respiratory tract infections found that rapid knowledge of a diagnosis led to a decrease in 
duration of antibiotic use by 3.8 days per patient, and a decrease in length of admission by 
0.9 days per patient, significantly reducing the costs of hospital care by up to 26%81.  Also 
important is the collection of epidemiological data to analyse patterns and implement 
management plans for infection control.   
The aim of this chapter is to characterise the viral and atypical bacterial causes of ARI in 
children under five years of age.  
4.2 Methods 
Nasopharyngeal aspirate (NPA) samples were analysed for 17 viral and atypical bacterial 
pathogens (human respiratory syncytial virus (hRSV), human rhinovirus (hRV), human 
metapneumovirus (hMPV), adenovirus (AdV), human bocavirus (hBoV), influenza virus A 
and B (flu), parainfluenza virus 1-4 (PIV), coronaviruses OC43, 229E, NL63 and HKU1 (CoV),  
Mycoplasma pneumoniae (Mpp) and Chlamydia pneumoniae (Cpp))using multiplex PCR as 
detailed in section 2.5.2. 
Results were analysed using SPSS 18.0.1 as detailed in section 2.7. 
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4.3 Results 
Multiplex PCR was performed on NPAs from each of the 407 children enrolled in the study, 
in order to detect the 17 different respiratory pathogens described above. Of the 407 
samples, 348 (85.5%) were found to be positive for at least one viral or atypical bacterial 
pathogen.  The most commonly detected pathogens were hRSV (detected in 152 (37.3%) 
samples), AdV (101, 24.8%), hRV (77, 18.9%), hBoV (76, 18.7%), hMPV (42, 10.3%) and Mpp 
(40, 9.8%). PIV was detected in 34 (8.4%) samples, CoV in 13 (3.2%), Flu in 11 (2.7%) and 
Cpp in 5 (1.2%) (Figure 7). The most common type of PIV detected was PIV3, found in 20 
(4.9%) samples; PIV4 was detected in nine samples; PIV1 in four samples and PIV2 in one 
sample. The most common CoV detected was CoV-OC43, found in 7 (1.7%) samples; CoV-
NL63 was detected in four samples; CoV-HKU1 in two samples and CoV-229E in one sample.  
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Figure 7: Pathogen prevalence  
Pathogen prevalence (%) in nasopharyngeal aspirates from children less than five years of age with 
acute respiratory infection. Cumulative prevalence is greater than 100% due to the presence of co-
infection. (AdV, adenovirus; hBoV, human bocavirus; Cpp, Chlamydia pneumoniae; CoV, 
coronaviruses; Flu, influenza viruses; hMPV, human metapneumovirus; Mpp, Mycoplasma 
pneumoniae; PIV, parainfluenza viruses; hRSV, human respiratory syncytial virus; hRV, human 
rhinovirus) 
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4.3.1 Co-infection 
Co-infection with two or more pathogens was detected in 161 samples (39.6%). Two 
pathogens were detected in 124 samples (30.5%); three in 33 samples (8.1%); four in three 
samples (0.7%); and one sample was found to contain five pathogens (Figure 8). 
Of the 187 single infections, the most common pathogens were hRSV, detected in 81 
samples (43.3%), followed by hRV, detected in 34 samples (18.2%), followed by hMPV, 
detected in 11 samples (5.9%). AdV and hBoV, which were overall the second and third 
most commonly detected pathogens, were found as single infections in only 16 (8.6%), and 
nine (4.8%) samples, respectively (Figure 9). 
AdV was found to be the most common pathogen involved in co-infection, being detected 
in 85 (52.8%) of the 161 samples. This was followed by hRSV, detected in 71 (44.1%) 
samples; and hBoV, detected in 67 (41.6%) samples (Figure 10).  
The most common combinations of co-infection were dual infections with hRSV and hBoV 
(26 samples; 16.1% of co-infections), hRSV and AdV (18 samples; 11.2% of co-infections), 
and hRV and AdV (12 samples; 7.5% of co-infections). Other combinations observed in over 
5 cases were hMPV and AdV, hMPV and hBoV, hMPV and Mpp, hRV and hBoV, PIV and 
AdV, and hRSV and hRV (Figure 11). The most common triple infection was found to be 
with AdV, PIV and hBoV (detected in 4 cases).  
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Figure 8: Number of pathogens detected per sample 
Number of pathogens detected by multiplex PCR in each nasopharyngeal aspirate sample from 
children less than five years of age with acute respiratory infection. 
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Figure 9: Pathogen frequency in single infection  
Pathogen frequency in nasopharyngeal aspirates found to contain only single infection, from 
children less than five years of age with acute respiratory infection. (AdV, adenovirus; hBoV, human 
bocavirus; Cpp, Chlamydia pneumoniae; CoV, coronaviruses; flu, influenza viruses; hMPV, human 
metapneumovirus; Mpp, Mycoplasma pneumoniae; PIV, parainfluenza viruses; hRSV, human 
respiratory syncytial virus; hRV, human rhinovirus) 
 
Figure 10: Pathogen frequency in co-infection  
Pathogen frequency in nasopharyngeal aspirates found to contain co-infection with multiple 
pathogens, from children less than five years of age with acute respiratory infection. (AdV, 
adenovirus; hBoV, human bocavirus; Cpp, Chlamydia pneumoniae; CoV, coronaviruses; flu, influenza 
viruses; hMPV, human metapneumovirus; Mpp, Mycoplasma pneumoniae; PIV, parainfluenza 
viruses; hRSV, human respiratory syncytial virus; hRV, human rhinovirus) 
0
10
20
30
40
50
60
70
80
90
AdV hBoV Cpp CoV Flu hMPV Mpp PIV hRSV hRV
Fr
e
q
u
e
n
cy
Pathogen
0
10
20
30
40
50
60
70
80
90
AdV hBoV Cpp CoV Flu hMPV Mpp PIV hRSV hRV
Fr
e
q
u
e
n
cy
Pathogen
85 
 
 
Figure 11: Most frequent co-infections  
Combinations of pathogens most frequently detected in nasopharyngeal aspirate samples found to 
contain co-infection with multiple pathogens. (AdV, adenovirus; hBoV, human bocavirus; hMPV, 
human metapneumovirus; Mpp, Mycoplasma pneumoniae; PIV, parainfluenza viruses; hRSV, human 
respiratory syncytial virus; hRV, human rhinovirus) 
 
 
 
0
5
10
15
20
25
30
Fr
e
q
u
e
n
cy
Pathogens
86 
 
The sample which was found to contain five pathogens contained hRSV, hMPV, hRV, hBoV 
and Mpp. On further investigation this child was found to be a one month old female, born 
at 39 weeks gestation with a normal birth weight (3400g), with no known co-morbidities 
and no previous hospital admissions. The child died in hospital from this episode, diagnosed 
as severe pneumonia. Her diagnosis was confirmed by chest x-ray findings.  
Two other infants in the study population died in hospital during their admission for ARI. 
The first was a five month old boy who had no known co-morbidities, a normal birth weight 
and birth history, and was diagnosed with severe pneumonia. PCR results found the child to 
have hRV infection. The other child who died during the study period was a seven month 
old boy who had neurological co-morbidities. He was admitted with severe pneumonia, and 
died after seven days in hospital. All pathogens tested for were negative. 
4.3.2 Pathogen detection and disease severity 
When the relationship between respiratory pathogen and disease severity was studied, 
hRSV and Mpp infection were the only pathogens associated with particular disease 
severities. Children found to have Mpp infection were more likely to be admitted with 
moderate (12.4%) or severe (16.7%) disease, than discharged with mild (6.4%) disease, 
when compared to those without Mpp infection (p=0.04; p=0.039, respectively). Children 
with hRSV infection were more likely to be admitted with moderate disease than mild 
disease, when compared to children without hRSV infection (43.2% vs 31.8%; p=0.019). 
Otherwise, the prevalence of pathogens within the disease severity groups was similar, and 
there was no significant difference in disease severity groups in patients from whom no 
pathogen was detected, or in whom co-infection was found.  
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Children with hRSV infection were significantly more likely to need admission than those 
without hRSV infection (59.2% vs 47.8%; p=0.017). Similarly, those with Mpp infection were 
also significantly more likely to require admission than those without (70.0% vs 53.6% 
p=0.017). Conversely, those with PIV infection were less likely to need admission than those 
without (35.3% vs 53.6%; p=0.031). 
4.3.3 Pathogen detection and clinical condition 
When the relationship between respiratory pathogens and clinical condition was studied, 
only Mpp infection and hBoV infection were associated with particular clinical conditions. 
Mpp infection was more commonly associated with pneumonia than bronchiolitis (13.8% of 
cases of pneumonia vs 7.1% of cases of bronchiolitis; p=0.04), when compared to children 
without Mpp infection. HBoV was more commonly associated with EVW/asthma than 
bronchiolitis (29.1% of EVW/asthma vs 14.7% of bronchiolitis; p=0.013). No other 
relationships between pathogen and particular clinical conditions were found. The 
proportion of patients from whom no pathogen was detected or in whom co-infection was 
found, was not significantly different in any of the four clinical condition categories.  
4.3.4 Seasonal Distribution 
The peak incidence of ARI was found to be between April and September, with 70% of 
infections presenting during these autumn and winter months (Figure 12). hRSV showed a 
clear peak in between April and July, with no cases observed between October and 
February, clearly defining the hRSV season in Brazil. hMPV was prevalent throughout the 
year but had a clear peak after the hRSV peak, in September and October. Mpp was found 
to have a strong peak in August, with 80.0% of positives being found between July and 
October.  AdV, hBoV and hRV were prevalent throughout the year. PIV, CoV, Cpp and flu all 
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had relatively few positive samples, meaning it is not possible to comment on a seasonal 
distribution. However, influenza was only detected between March and May, with one case 
also in July. 
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Figure 12: Seasonal distribution  
Seasonal distribution of the most frequently detected pathogens in nasopharyngeal aspirates from 
children less than five years of age with acute respiratory infection. (AdV, adenovirus; hBoV, human 
bocavirus; hMPV, human metapneumovirus; Mpp, Mycoplasma pneumoniae; hRV, human 
rhinovirus; hRSV, human respiratory syncytial virus). 
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4.3.5 Relationships with age 
The median (range) age of study participant was 8 (0-57) months. The median (range) age 
of study participant in the hMPV positive, hRSV positive and hRV groups were all lower than 
that of the population median (hMPV 5.5 months [1-36]; hRSV 6.0 [0-57]; hRV 6.0 [0-56]). 
The groups with the highest median age were found to be Cpp (11 months [4-15]), and CoV 
(13 months [1-57]). However, care needs to be taken when analysing this data as there is 
overlap between groups due to the high levels of co-infection in the study population. 
4.3.6 PCR Negative Samples 
Of the 59 children whose samples were found to be negative for all 17 pathogens, six 
(10.2%) were found to be very mild infections, 26 (44.1%) mild, 21 (35.6%) moderate and 
six (10.2%) severe. The diagnoses of these children were found to be bronchiolitis in 28 
(47.5%), pneumonia in 16 (27.1%), episodic wheeze in 7 (11.9%), URTI in 6 (10.2%) and 
laryngotracheobronchitis and whooping cough each in one case.  
4.4 Discussion 
In this chapter we have used multiplex PCR to simultaneously detect 17 different 
respiratory pathogens in NPAs from a population of children and infants under the age of 
five, presenting with acute respiratory infection.  
The overall positive rate, finding 85.5% of samples positive for one or more pathogens, was 
particularly high when compared to similar study populations. Regamey et al. found 79% of 
samples taken from children age 0 to 1 year, presenting with their first ARI, positive for one 
or more pathogen, when testing for 16 different respiratory viruses1. Other studies have 
found varying overall positive rates, ranging from 35.2% to 74%, although all were testing 
for varying numbers of viruses, ranging from 7 to 211 10 13 15 33 45 54.  
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The prevalence of hRSV, AdV and hBoV are all very high in the study population. hRSV has 
been found to be more prevalent in other studies, but these were looking specifically at 
bronchiolitis or children under the age of one157. Many other studies have found the 
prevalence of AdV to be below 10%1 10 45 54 148 158. Fewer studies have investigated the 
prevalence of hBoV, due to its more recent discovery in 2005, but the prevalence has been 
found to be between 2.2 and 18%33 46 157 158.  
The co-infection rate of 39.5% is higher than previously reported. Other studies have 
reported co-infection rates to be between 4 and 33% when using multiplex PCR to test for 
respiratory pathogens1 13 45 46 54. 
There are a number of possible reasons for the high detection and co-infection rates. This 
study looked for 17 respiratory pathogens, which is more than most similar studies1 10 13 33. 
All samples were NPAs collected by one research assistant, using a standard, reproducible 
protocol. Also, the demographics of the study population, as described in chapter 3, 
suggest that most children came from low income families, living in crowded environments, 
where living conditions may well facilitate the spread of pathogens. 
 AdV and hBoV were found to be particularly prevalent in our study population, and were 
found to be the first and third most common pathogens to be involved in co-infection. 
Previous studies have found both much lower prevalences of AdV and hBoV, along with 
much lower prevalences of co-infection1 33 45. The high rates may be due to prolonged 
nasopharyngeal shedding of the viruses post-infection. AdV has been detected in faeces 
months after infection159, although it is unknown whether a similar situation occurs in the 
nasopharynx. A recent study detected hBoV in nasopharyngeal aspirates from three 
children, at least two months following their acute infection67. 
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One study that has found prevalence rates of particular viruses to be very high, similar to 
those described here, is that by Kaplan et al. who studied a similar population of children 
under five years of age in Jordan. They described the prevalences of AdV and hBoV to be 
37% and 18%, respectively46. Interestingly, they are also the only other study to have found 
similar co-infection rates (33%). However, they found the prevalence of hRV (11%) and 
hMPV (2.5%) to be much lower than those described here, and they found no cases of Mpp 
or PIV46. 
Seasonal Distribution 
The seasonal distribution graphs show the hRSV season to be between March and August – 
Brazil’s rainy season. Although hRSV is known to have a strong seasonal distribution, 
peaking in winter months, Recife has a tropical climate, with little variation in temperature 
throughout the year. It is somewhat surprising, then, that there is such a strong seasonal 
distribution, with no hRSV detected between October and February. 
The Mpp results were particularly interesting, with a clear peak in the winter month of 
August, which was not expected. The prevalence of Mpp in the study population was also 
interesting, being higher than expected. Mpp is typically thought to affect older children 
and young adults148, and is not thought to be one of the more common causes of 
pneumonia in pre-school children.  These results may have implications for treatment of 
these children in this setting, as Mpp infections are treated with macrolide antibiotics such 
as erythromycin. This is in contrast to the supportive treatment of the viral pathogens or 
the antibiotic treatment of S. pneumoniae or Haemophilus influenzae, bacterial pathogens 
more commonly associated with pneumonia in this age group.   
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The three children included in the study population who died during their admission for ARI 
are all very interesting cases. The first child was one month old, previously healthy with a 
normal birth history and no previous admissions. The fact that she was admitted with 
severe pneumonia and then found to have five different respiratory pathogens in her NPA 
is surprising for a child of such a young age. She may have been very unlucky, coming into 
contact with five infections in her four weeks of life, which may reflect living conditions. 
Another possibility is that she had some form of underlying problem such as a congenital 
cardiac defect, or some form of immunocompromise, which predisposed her to ARI.  
Unfortunately, as the PCR results were only discovered during the study, after the child’s 
death, it was not possible to confirm this. The second child who died during the study 
period was a five month old boy, again with no co-morbidities and an unremarkable past 
medical and birth history. This child was only discovered to have hRV in his sample. Human 
rhinoviruses are the most common respiratory tract viruses in older children and adults, 
and are thought to cause about two-thirds of common colds and asthma exacerbations10. 
They are most well known to cause upper respiratory illness, and are not specifically 
associated with severe illness. This child’s death could be due to a number of factors. 
Although the majority of ARI are caused by viruses, some are caused by bacteria, and 
although we tested for 17 different respiratory pathogens, we only tested for two bacteria. 
This child’s particularly severe illness could be because of a dual infection with hRV and 
another bacterial pathogen, or another viral pathogen which was not tested for. 
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5 Cytokine Analysis 
5.1 Introduction 
To further elucidate the pathogenesis of acute respiratory infection (ARI), and the 
complicated interplay between the pathogen and the host immune response, several 
studies have investigated cytokine profiles in the respiratory tract during ARI. The ideal way 
to investigate cytokine profiles would be to compare cytokine responses in healthy 
controls, to those with ARI. However, as previously mentioned, control subjects are difficult 
to recruit to this type of study and the nasopharynx is dry and difficult to sample in people 
without respiratory symptoms. 
There is much conflicting evidence in the literature on the links between particular 
cytokines and chemokines and severity of disease in ARI. For example, one study reported 
an association between low levels of IL-6, IL-8, IL-10, IFN-γ and MIP-1β and a longer 
duration of supplemental oxygen therapy in children with RSV bronchiolitis160. However, 
strong associations between IL-8 and increased severity of disease have also been shown161.  
 Many studies have looked at only one or two cytokines, or looked specifically at children or 
infants with bronchiolitis alone161-163. More evidence is therefore needed on which to draw 
conclusions on the relationship between the inflammatory response and disease severity in 
ARI. 
Few studies have investigated the relationship between inflammatory response in the 
airways in relation to the particular pathogen involved in ARI. McNamara et al in 2007 
found no difference in the concentration of a variety of cytokines and chemokines in 
bronchoalveolar lavage (BAL) samples from children with severe bronchiolitis caused by 
hRSV, compared to those with hRSV/hMPV co-infection162. Byeon et al in 2009 investigated 
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IL-4, IL-5 and IFN-γ levels in children with hRSV, influenza (flu), parainfluenza virus (PIV) and 
adenovirus (AdV) infection163. This study found significantly lower levels of IL-4 and IL-5 in 
the flu group when compared to the other three groups, in which they found a pattern of 
increased IL-4 and IL-5 levels, and decreased IFN-γ levels163. Again, these studies all 
investigated different aspects of the immune response, and where there was overlap 
between studies, results were not consistent.  
The aims of this part of the study were to characterise the inflammatory response in 
nasopharyngeal aspirate (NPA) samples from previously healthy children under the age of 
five with acute respiratory infection (ARI). The following hypotheses were investigated: 
1. Different severities of hRSV disease are characterised by different host immune 
responses 
2. Host immune responses in infection vary depending on infecting pathogen. 
5.2 Methods 
5.2.1 Patient Samples 
To maximise the number of samples containing single infection, samples from the following 
year’s recruitment were also included. 
hRSV Severity Groups 
Initially the aim was to select equal numbers of samples containing only hRSV infection 
from each of the four severity groups: very mild, mild, moderate and severe, for cytokine 
analysis. However, even though hRSV was found to be the most prevalent pathogen in the 
study population, the exceptionally high prevalence of co-infection meant that the number 
of samples with hRSV infection alone was 81, with only six being very mild infections, and 
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only seven being severe infections. A total of 47 samples were selected for analysis, 
including six very mild, nineteen mild, fifteen moderate and seven severe. 
Various Pathogen Groups 
A second experiment was used to determine cytokine profiles in samples infected with 
different pathogens in order to test the hypothesis ‘host immune responses in infection 
vary depending on infecting pathogen’. Samples containing the following pathogens were 
selected for cytokine analysis on the basis of numbers of single infections by that particular 
pathogen: human metapneumovirus (hMPV), human rhinovirus (hRV), Mycoplasma 
pneumoniae (Mpp), adenovirus (AdV), and human bocavirus (hBoV). hRSV samples were 
not tested as data for these samples would already be available from the hRSV severity 
experiment. Samples with coronavirus (CoV), parainfluenza virus (PIV), influenza (flu) virus 
and Chlamydia pneumoniae (Cpp) were not selected for study due to the small sample size 
of single infection in each of the groups. Due to the high level of co-infection, only nine 
Mpp samples were available for analysis; all other groups contained ten samples.  
5.2.2 Cytokine Analysis 
Cytokine profiles of the NPA samples were determined using a human cytokine 8-plex bead 
immunoassay kit, along with a singleplex IL-17 kit as detailed in section 2.6.  
A protein assay was performed to determine the protein concentration of each sample. 
Cytokine concentrations were then adjusted according to protein content and expressed as 
pg/ml/mg protein.  
5.2.3 Statistics 
The relationship between cytokine concentrations and different disease severities or 
pathogens was studied using a Kruskall Wallis test. Where differences were detected 
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between the groups, a Mann Whitney U test was used to find which groups were 
statistically different, with a p-value <0.05 being considered statistically significant. 
Statistical analysis was performed using SPSS 18.0.1 statistical package (SPSS Inc, Chicago). 
5.3 Results 
A total of 103 samples were analysed for the presence of nine different cytokines. IL-6, IL-8, 
IL-10 and GM-CSF had detectable concentrations in over 90% of samples, IL-17, IL-4 and 
TNF-α had detectable concentrations in 65-75% of samples, and IFN-γ and IL-2 had 
detectable concentrations in 50.1% and 33.7%, respectively.   
5.3.1 hRSV severity samples 
A total of 47 NPA samples containing single hRSV infection were analysed for the presence 
of nine different cytokines. One sample (moderate severity) was excluded due to a low 
protein concentration that was below the detection range of the standard curve, bringing 
the total number of samples for analysis to 46. 
Demographics 
The median (range) age of the study participants in this group was 4 (0-20) months. The age 
of participants in each of the severity groups were not significantly different. Overall 52.2% 
(24/46) were males. The diagnoses included URTI (15.5%); bronchiolitis (58.7%) and 
pneumonia (26.1%). 
Cytokine Concentrations 
Figure 13 demonstrates the concentrations of IL-4, IL-6, IL-8, IL-10, GM-CSF, INF-γ and TNF-
α found in nasopharyngeal aspirate samples from children with single hRSV infection, with 
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very mild, mild, moderate and severe disease. All results are shown as medians and inter-
quartile ranges. 
The results have been grouped according to function of the specific cytokines. The first 
shown are the innate, pro-inflammatory cytokines, IL-8, GM-CSF, IFN-γ and TNF-α. Next is 
IL-4, an adaptive, Th2 cytokine. Finally there are IL-6, IL-17 and IL-10, which have been 
grouped together due to their regulatory functions, with IL-6 included here due to its 
effects on IL-17 production. 
From the graphs you can see the wide variation in the range of results both within and 
between groups. After statistical analysis using a Kruskal-Wallis test, there was found to be 
no significant difference between cytokine concentrations according to severity of hRSV 
infection. 
Although statistical analysis revealed no significant differences between groups, some 
patterns can be seen, particularly in the IL-4 and IL-10 graphs, with increasing IL-4 and IL-10 
with increasing severity. Levels of GM-CSF also appear to increase with increasing severity, 
while levels of IFN-γ appear to be lower in the moderate and severe groups.  
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Figure 13: Cytokine concentrations in varying severities of single hRSV infection.   
Concentrations of IL-8, IFN-γ, TNF-α, GM-CSF, IL-4, IL-6, IL-10 and IL-17 were measured in NPA 
samples from patients who had very mild (n=6), mild (n=19), moderate (n=15) and severe (n=7) hRSV 
infection. Samples were diluted 1:6 and all results were adjusted according to protein concentration. 
All values shown are pg/ml/mg protein. Outliers have been omitted from the graphs.   
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5.3.2 Cytokine Responses to Various Pathogens 
A total of 49 samples which had tested positive for a single pathogen (hMPV, hRV, Mpp, 
AdV or hBoV) were analysed for the presence of nine different cytokines. Two samples 
(both Mpp) were excluded from the analysis due to low protein concentrations. The total 
number of samples included was therefore 47, including hMPV (n=10), hRV (n=10), Mpp 
(n=7), AdV (n=10) and hBoV (n=10). The previous hRSV results (n=46) were also included, 
bringing the total number of samples for analysis to 93. 
Demographics 
Of the 93 samples analysed, 54 (58.1%) were from patients who were male. The median 
(range) age was 6 (0-48) months. Samples in the hRSV group were from significantly 
younger children than either the AdV group (p=0.002) and the hBoV group (p=0.004). The 
ages across all other groups were similar. The most common diagnoses were bronchiolitis 
(52.7%); pneumonia (32.3%); URTI (9.7%) and EVW/asthma (5.4%). A total of six (6.5%) 
cases were very mild; 33 (35.5%) mild, 41 (44.1%) moderate, and 13 (14.0%) severe. 
Cytokine Concentrations 
Figure 14 demonstrates the concentrations of IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, GM-CSF, IFN-
γ and TNF-α, according to the presence of pathogen: hMPV, AdV, Mpp, hBoV and hRSV. 
Again, large ranges both within and between groups can be observed.  
After statistical analysis, Kruskall-Wallis testing revealed differences between cytokine 
concentrations according to pathogen in IL-2 (p=0.039); IL-8 (p=0.001) and IL-17 (p=0.020). 
A Mann-Whitney U test was performed to detect where the differences were. After 
Bonferroni correction it was found that samples containing hRSV were associated with 
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significantly lower concentrations of IL-8 than hRV (p=0.001). There were no other 
significant differences in cytokine concentration according to pathogen. 
The available data was also analysed according to some of the demographic factors. It was 
found that there was no significant difference in cytokine concentrations according to 
clinical diagnosis or gender. When investigating cytokine concentrations according to age, 
infants under three months of age were found to have significantly lower concentrations of 
IL-2 (p=0.041), and significantly higher levels of IL-4 (p=0.013) and IL-10 (p=0.030) than 
those older than three months of age. No differences in cytokine concentrations were 
found according to severity of disease, which is similar to the previous findings when 
looking at hRSV infection alone.  
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Figure 14: Cytokine concentrations according to pathogen. 
All values shown are pg/mL/mg protein. Concentrations of IL-8, IFN-γ, TNF-α, GM-CSF, IL-2, IL-4, IL-6, 
IL-10 and IL-17 were measured in NPA samples from patients who had hMPV (n=10), AdV (n=10), 
hRV (n=10) Mpp (n=7), hBoV (n=10) and hRSV (n=46) infection. Samples were diluted 1:6, and all 
results were adjusted according to protein concentration. All values shown are pg/ml/mg protein. 
Outliers have been omitted from the graphs. (hMPV, human metapneumovirus; AdV, adenovirus; 
hRV, human rhinovirus; Mpp, Mycoplasma pneumoniae; hBoV, human bocavirus; hRSV, human 
respiratory syncytial virus). 
105 
 
5.3.3 Cytokine responses to co-infection 
 Very recent work which was presented at the American Thoracic Society conference in 
May 2010, investigated the role of IL-17 in the immune response to bacteria. Using a mouse 
model they found bacterial infection to be associated with a strong IL-17 response, while 
viral co-infection inhibited bacterial induced IL-17 production through interferon mediated 
inhibition of IL-23164. 
In light of this recent work, and the exceptionally high rate of co-infection observed in our 
study, cytokine responses and specifically IL-17 responses were investigated in single 
bacterial infection and viral/bacterial co-infection.  
Therefore, as the final part of this study, 10 samples containing co-infection with a 
bacterium (Mpp) and a virus (hRV (n=3), AdV (n=4), hBoV (n=3)) were also tested for the 
same nine cytokines (IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-γ, TNF-α), using the same 
protocol and protein analysis as described previously. These results were then compared to 
those of atypical bacterial infection alone, to determine whether viral co-infection had an 
effect on the IL-17 response. 
Demographics 
The median (range) age in this co-infection group was 10 (3-48) months, which was not 
significantly different from that of the Mpp group. Six samples were from male patients, 
and four from females. Three samples were classed as mild, four as moderate, and three as 
severe. The diagnoses were bronchiolitis (n=6), pneumonia (n=2) and episodic viral 
wheeze/asthma (n=2).  
Cytokine concentrations 
Due to the small sample size of each group, the co-infection results were grouped together 
for analysis, and compared to results from Mpp samples alone.  
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All samples had adequate protein concentrations.  
Figure 15 demonstrates the concentration of IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, GM-CSF, IFN-γ 
and TNF-α, in samples with bacteria/virus co-infection, when compared to bacterial 
infection alone.  After statistical analysis using a Mann-Whitney U test, several significant 
differences were detected. The bacteria/virus co-infection group was found to be 
associated with significantly lower levels of TNF-α, IL-4, IL-10 and IL-17, when compared to 
Mpp infection alone.   
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Figure 15: Cytokine concentrations according to single infection with Mpp, or co-infection with 
Mpp/virus. 
Concentrations of IL-8, IFN-γ, TNF-α, GM-CSF, IL-2, IL-4, IL-6, IL-10 and IL-17 were measured in NPA 
samples from patients who had single Mpp infection (n=7) and Mpp/virus co-infection (n=10). 
Samples were diluted 1:6, and all results were adjusted according to protein concentration. All 
values shown are pg/ml/mg protein. - indicates outliers. All other outliers have been excluded from 
the graphs as they did not influence significance. (Mpp, Mycoplasma pneumoniae) 
 
p=0.002 
p=0.001 
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5.4 Discussion 
In this chapter we have described host immunological responses in acute respiratory 
infection (ARI), investigating the concentrations of nine different cytokines in 
nasopharyngeal aspirate (NPA) samples from children with ARI with varying severities of 
human respiratory syncytial virus (hRSV) infection, varying pathogens, and bacterial/viral 
co-infection. We did not observe any differences in cytokine concentrations associated with 
differing severities or pathogens.  
Throughout this part of the study, results were adjusted according to protein concentration 
of the sample. This was done to adjust for any variability in sample quality. Conversely, 
adjusting for protein may have affected the results by disguising true differences in 
cytokine concentration. For example, a more severe sample may have had a higher protein 
concentration because of the response to the particular pathogen. 
5.4.1 Cytokine response to varying severities of hRSV infection 
Similar cytokine concentrations were observed across different severity groups possibly due 
to the small sample size in each severity group. The very mild and severe groups were 
particularly small (n=6 and n=7, respectively), due to limitations in the number of these 
samples that were available for testing because of the high level of co-infection. This may 
have been important, as if a difference in response were to exist, it would be expected that 
it may be in one of these two groups, at either end of the severity spectrum.  
In addition, although all samples were hRSV positive, with no known co-infections, the age 
range varied throughout the group, and the diagnoses were varied between bronchiolitis, 
pneumonia, upper respiratory tract infection, and episodic viral wheeze/asthma. Previous 
studies have tended to focus on one particular group, such as hRSV bronchiolitis161, which 
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may have affected findings. Also, co-infection with either common bacterial infection such 
as S. pneumoniae, or with as yet undiscovered viruses, cannot be excluded. Interferon anti-
viral responses were not fully investigated in this study. It is possible that differences in 
severity may be attributable to insufficient amounts of these cytokines, such as IFN-α and 
IFN-β, being produced. 
Furthermore, the samples investigated were nasopharyngeal aspirates, which may not be 
representative of what is happening in the lower respiratory tract, which is where the 
infections manifest and cause clinical problems. However, one particular study compared 
IL-2 levels in NPA and BAL samples in children with hRSV bronchiolitis, finding no significant 
difference between the groups165, indicating that NPAs do provide a good insight of what is 
going on in the lower respiratory tract.   
Although no significant differences in cytokine concentration were found with regard to 
varying severities of disease, patterns could be observed when looking at some of the 
graphs. It appeared that IL-4 and IL-10 levels increased with increasing severity. IL-4 is a Th-
2 cytokine, and has been found to be increased in murine models following stimulation 
with the RSV G protein132. IL-10 is a regulatory cytokine, with effects on the production of 
pro-inflammatory cytokines. Increased IL-10 levels in increased severity of disease may lead 
to thinking that the inhibition of pro-inflammatory cytokines may be an important factor in 
preventing the removal of pathogens and their harmful effects, consequently causing more 
severe disease. IFN-γ levels appeared to decrease with increasing severity of disease. This 
would fit with increasing IL-10 levels, with IFN-γ being one of many pro-inflammatory 
cytokines which would be inhibited by IL-10’s regulatory effects. However, levels of GM-
CSF, another pro-inflammatory cytokine, appeared to increase with increasing severity. This 
would not be expected with increasing levels of IL-10 – the opposite would be expected, as 
111 
 
with the IFN-γ levels. These were just patterns observed from the graphs, and the study 
would need to be furthered with a larger sample size to look further at these patterns, and 
identify whether or not they became significant trends.  
Bennett et al in 2007 reported an inverse relationship between levels of IL-6, IL-8, IL-10, 
IFN-γ and macrophage inflammatory protein-1β (MIP-1β) and the need for oxygen therapy 
in nasal wash samples from children with bronchiolitis160. The study also found that levels 
of IL-6, IL-8, GM-CSF, IFN-γ, TNF-α, IL-1β, GM-CSF and MIP-1β were all increased in children 
with hRSV bronchiolitis, compared to those with non-hRSV bronchiolitis, although the 
severity of disease did not differ between the two groups. When investigating children with 
hRSV bronchiolitis alone, this group found that cytokine/chemokine levels were not 
significantly different in relation to the need for hospitalisation160. 
Although Bennett et al investigated a wide range of cytokines/chemokines, and had a fairly 
large sample size, there were several limitations to this study. Firstly, although the presence 
of other viruses were investigated in the samples, the effects of other viruses on 
inflammatory responses were not mentioned, and these may have had a confounding 
effect not only on the results from the ‘non-hRSV’ group, but also on the hRSV group with 
co-infection. Also, no bacterial pathogens were tested for, which may also have had 
confounding effects. 
In contrast other studies have reported IL-8 to be closely correlated with severity of hRSV 
disease134 161. Smyth et al in 2002 found a strong association between increased IL-8 mRNA 
in NPAs and severe hRSV bronchiolitis161. This also agreed with the findings by Hull et al in 
2000, who found an association between a single nucleotide polymorphism (SNP) near the 
IL-8 transcription site, causing increased IL-8 production, and increased severity of hRSV 
bronchiolitis134. Another study looking specifically at cytokine profiles from children with 
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AdV infection found no increase in IL-8 concentrations in nasal wash samples from children 
with AdV infection, when compared to healthy controls166.  However, this same study did 
find an increase in IL-8 levels in patients admitted to hospital who were found to have AdV 
infection, compared to those who had AdV infection but were not admitted166. One other 
study investigated IFN-γ levels in infants with hRSV lower respiratory tract infection (LRTI), 
finding significantly decreased levels in infants with severe disease who required 
ventilation167.  
This, along with other studies that have looked specifically at one cytokine or one particular 
clinical condition, has demonstrated that there is an array of conflicting evidence, and lack 
of consensus as to whether individual cytokines have a role in the severity of disease. 
Previous studies163 have illustrated theories that cytokine levels vary depending on virus 
and viral load, while other studies160 161 168 have postulated that it is the inflammatory 
response, or lack of it, that may be causing increased disease severity. Our results do not 
show an association between cytokine concentrations and disease severity in single hRSV 
infection, and further study with a bigger sample size is needed to attempt to further 
understand the complex mechanisms and pathogenesis of this virus in the lungs.  
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5.4.2 Cytokine responses to various pathogens 
 A total of 46 samples containing hMPV, hRV, AdV, Mpp, hBoV and hRSV infection were 
tested for various different cytokines. After correcting for multiple comparisons the only 
significant difference was found between the concentration of IL-8 in hRSV compared to 
hRV. However, there are many other confounding factors that were not taken into account, 
including age. The samples in the hRSV group were from significantly younger children than 
two of the other groups. We are not able to determine whether, in this case, the difference 
in cytokine concentrations is due to the child’s age, the hRSV infection, or another 
confounder that we have not investigated. Although age was not significantly different in 
any of the other groups, factors such as prematurity, breastfeeding and living conditions 
were not investigated or adjusted for. These are all factors that could affect immune 
responses and therefore may have an effect on cytokine concentrations.  
The cytokines measured are all characteristic of a broad immune response to infection in 
the lung, and our results reflect a general response. This is not surprising when looking at 
the innate cytokines, where the aim of the innate response is to alert the adaptive immune 
system to the infection and to use non-specific mechanisms to destroy the pathogens, or at 
least keep the level of infection under control. 
Previous studies that have investigated cytokine responses to different pathogens have 
found conflicting results. McNamara et al in 2002 investigated cytokine concentrations in 
bronchoalveolar lavage (BAL) samples from infants ventilated for bronchiolitis, with regard 
to the presence of single hRSV infection, or hRSV/hMPV co-infection. In this study clinical 
characteristics were similar between groups. No differences were detected in cytokine     
(IL-4, IL-9, IL-10, IL-13, TNF-α and IFNγ) or chemokine concentrations between the single 
infection or co-infection groups162. Byeon et al in 2009 investigated the response to IL-4, IL-
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5 and IFN-γ in NPAs from children with LRTI caused by various pathogens. They found that 
hRSV, PIV and AdV infections caused a Th2 skewed response, with increased production of 
IL-4 and IL-5 and decreased IFN-γ, in comparison to influenza virus infection which was 
associated with significantly lower levels of IL-4 and IL-5163. 
Again the literature demonstrates many conflicting results, with a lack of large studies into 
this area.  
5.4.3 Cytokine responses to co-infection 
The final part of this study investigated cytokine concentrations of 10 samples with 
bacteria/virus co-infection. The bacteria/virus co-infection group was associated with 
significantly lower levels of several cytokines.  
 The IL-17 response is interesting, as recent work described by Alcorn et al. described the 
inhibitory effects of influenza A on IL-17 and IL-22 production and the subsequent increased 
inflammation and decreased clearance of bacterial infection with Staphylococcus aureus164. 
We have observed significantly lower levels of IL-17 in the bacteria/virus group, when 
compared to single bacterial infection with Mpp. However, the IL-17 responses to 
bacteria/virus co-infection are similar to those with virus alone, which leads to the 
question: is the Mpp in these infections active virus? The high sensitivity of PCR means that 
there is a possibility that we are picking up remnants of an older Mpp infection, and in fact 
what we are seeing in these results is caused by viral infection alone.  
The low IFN-γ response in the co-infection group is interesting. As an innate cytokine 
involved in the defence against both viral and bacterial pathogens it would be expected to 
demonstrate a larger response in this group. However, we have not investigated IFN-α or 
IFN-β – the type I interferons which are important in the innate response to viral infection. 
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It may be the case that these type I interferons, or another cytokine or mediator we have 
not investigated, may be having the predominant effects.  
Studies investigating the link between viral infection and increased susceptibility to 
bacterial infection have proposed various theories on the likely mechanisms. One particular 
study using a murine model found influenza virus to inhibit clearance of Streptococcus 
pneumoniae by decreasing tracheal mucociliary velocity – reduced clearance of mucus 
provides an ideal environment for pathogens169. Wang et al found that rhinovirus infection 
led to increased adhesion of Staphylococcus Aureus, Streptococcus pneumoniae and 
Haemophilus influenzae in primary human nasal epithelial cells, which was caused by 
increased production of fibronectin and other adhesion molecule receptors170.  
These mechanisms, as well as those proposed by Alcorn et al, should all be considered 
when interpreting the high levels of co-infection in this study. Further study, particularly on 
mechanisms involving co-infections with adenovirus and bocavirus, which have been shown 
in particularly high levels in this study, would be of interest.  
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6 Discussion 
In this thesis we have described detailed demographic and clinical characteristics of 
children under the age of five in Recife, Brazil, with acute respiratory infection (ARI). We 
have investigated the causes of ARI by using multiplex polymerase chain reaction (PCR) to 
detect 17 different viral and atypical bacterial respiratory pathogens in nasopharyngeal 
aspirates (NPAs) from these children. In the final chapter we investigated cytokine profiles 
in NPAs from a selection of these children, looking at samples with differing severities, 
different pathogens and co-infection. 
Using a questionnaire to ascertain details on the demographics of the study population we 
found several factors that suggest the population studied had a lower socio-economic 
status than in Brazil as a whole, with indicators such as family income, level of schooling 
and overcrowding. PCR results demonstrated a high level of PCR positive samples, high co-
infection rates, and particularly high levels of adenovirus (AdV), human bocavirus (hBoV) 
and Mycoplasma pneumoniae (Mpp) infection. Mpp infection and human respiratory 
syncytial virus (hRSV) infection were associated with increased likelihood of admission to 
hospital. No other pathogens or co-infection were associated with severity.  
Cytokine analysis of a selection of samples revealed similar cytokine concentrations across 
varying severities of hRSV infection, and with various pathogens.  
6.1 Strengths of the study 
This study has many strengths. The sample size of our study was large, including 407 
participants enrolled over a 12 month period. Most similar studies have investigated study 
populations with a smaller sample size1 10 13 15. Those studies that have been larger have 
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often looked at all ages, including adults and children, rather than looking specifically at one 
age group54 148. 
All NPAs taken were collected by one research assistant, using a systematic and 
reproducible method, ensuring all samples were of as high quality as possible.  
The questionnaire on demographic and clinical information was very thorough, and 
included a large number of questions covering a range of demographic and clinical topics. 
Each study participant was taken through the questionnaire with a research assistant, so 
that any queries could be answered, and so all questions were answered fully. 
We investigated the presence of 17 different common viral and atypical bacterial 
respiratory pathogens. Previous studies using multiplex PCR have investigated between 
seven and 21 different pathogens. However, the studies investigating 20 and 21 pathogens, 
found positive rates of 47% and 68%, respectively, both figures lower than our 85.5%45 54.   
Our study included children with a whole spectrum of ARI disease severity, from very mild 
upper respiratory tract infections (URTI), which would include children with runny noses, to 
severe cases of bronchiolitis and pneumonia, requiring oxygen and in some cases 
ventilation and intensive care admission. Many other studies have focused on one 
particular group, whether it be inpatients or outpatients, or specific groups such as those at 
high risk of atopy1 33 45 71.   
6.2 Limitations 
6.2.1 Demographics and clinical information 
The questionnaire on demographic and clinical information was very thorough, with a vast 
number of topics being covered. However, upon analysing the results and comparing to 
118 
 
data in the literature, it was identified that although questions were asked related to the 
presence of smokers in the household, no specific question was asked about maternal 
smoking during pregnancy. Therefore associations between maternal smoking during 
pregnancy and severity of ARI could not be made from this study, as reported in the 
literature171.  
The accuracy of clinical diagnosis of each child’s condition made by the attending physician 
upon discharge was one limitation of this study. Differentiating between bronchiolitis and 
pneumonia is particularly difficult in infants and young children. Information like this is 
always going to be a subjective assessment, and although it could have been made slightly 
more accurate using radiographs to investigate consolidation which may indicate 
pneumonia, studies have shown this to be a poor way of differentiating between 
pneumonia and bronchiolitis, with overlap between the signs shown in each condition88. 
However, despite being a limiting factor, it is representative of what happens in real clinical 
situations.  
The nature of the study design - a prospective, cross-sectional study – gives a snap-shot of 
this particular population of children at this moment in time. Only those who were brought 
to hospital were included in the study, and although this has included a wide spectrum of 
conditions and severities, as demonstrated by the inclusion of very mild and severe cases, 
there will be a large proportion who did not attend hospital, or may have sought medical 
care elsewhere. This means that the results can only be applied to a hospital based 
population, and may not be representative of the population as a whole. 
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6.2.2 PCR Results 
This study has successfully detected pathogens in 85.5% of NPAs, a higher percentage than 
has been previously reported in a similar population13 45 46 71. However this still leaves 14.5% 
of samples in which no pathogen was detected. A possible explanation for this is that this 
disease was caused by ‘typical’ bacteria. However, performing multiplex PCR looking for S. 
pneumoniae on NPA samples such as the ones collected in this study would have yielded 
inaccurate results, with previous studies finding over 60% of two year olds being 
asymptomatic carriers of the bacterium in their nasopharynx35. There would therefore be 
no way of determining if a positive result actually indicated that S. pneumoniae was 
responsible for the ARI. The collection of blood samples from each child, particularly to 
determine the full blood count (FBC), with differential white cell count, as well as the C-
reactive protein (CRP), would have provided an insight into systemic response to infection, 
and may have indicated the likelihood of a bacterial infection. Unfortunately collecting 
blood samples was not included in the initial study design, and only a very small number of 
children in the study had blood taken as part of normal clinical protocols. 
A further explanation of PCR negative samples within our study population would be the 
likelihood that there are as yet undiscovered respiratory pathogens, which may cause 
disease. Several new viruses have been discovered in recent years60 62 63, and it is likely that 
more will be discovered in the future. The sensitivity and specificity of the PCR assays used 
may be another explanation for some of the PCR negative samples. Even though PCR has 
been shown to be the most sensitive and specific way to rapidly identify and detect 
respiratory pathogens, especially in comparison to more traditional methods, no method is 
going to be 100% sensitive and specific172. 
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Tuberculosis (TB) was not looked for as part of this study protocol. The incidence of TB in 
Brazil was estimated by the World Health Organisation to be 45 per 100,000 population in 
2009173. This is a further limitation to the study, as although the uptake of the BCG vaccine 
was very high, it is not 100% effective – it is estimated that it reduces the risk of TB by 
50%174. With a high incidence of TB in the country, the possibility of TB in the study 
population cannot be discounted.  
As mentioned in chapter 4, due to the sensitivity of PCR, and its ability to amplify DNA from 
both active pathogens, and remnants of old pathogens, we are unable to confidently say 
that the pathogens we have detected are the cause of the child’s admission to the accident 
and emergency (A&E) department. A study using control samples to detect pathogens in 
asymptomatic children would help determine the likelihood of these pathogens being 
active, by giving base-line prevalence levels in the general population.  
The only known study to date that has investigated control samples in a similar situation is 
that by van der Zalm et al in 2009175. They carried out a prospective, longitudinal study, 
following 18 healthy children, aged between zero and seven years, with the parents taking 
biweekly nasopharyngeal and oropharyngeal swabs both when the children were 
asymptomatic or when they had respiratory symptoms. The study used PCR to look for the 
presence of 13 pathogens. They found 56% of samples taken from symptomatic children to 
be positive for at least one virus, but they also found 40% of samples from asymptomatic 
children to be positive175. The most common viruses in asymptomatic children were found 
to be hRV (detected in 22%); coronaviruses (8%) and Cpp (5%). They also detected co-
infection with multiple pathogens in 3% of samples175. AdV was not detected in any of the 
asymptomatic samples. These results are very interesting, with no other studies with 
similar data available. However, there are some limitations to this study. Firstly, they only 
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studied 18 children, and from these a total of 65 asymptomatic samples. Some samples will 
have come from the same children and the same latent pathogens may have been picked 
up multiple times from the same child. Also, the study only looked at a six month period, 
covering a only winter and beginning of spring seasons. A larger study investigating a 
control group over a longer period of time would be very interesting.  
The statistics performed on the data only detected differences in severity due to the 
presence of Mpp infection and hRSV infection; and only detected differences in clinical 
diagnosis due to the presence of Mpp infection and hBoV infection. However, the sample 
size of the ‘very mild’ and ‘severe’ groups was much smaller than that of the ‘mild’ and 
‘moderate’ groups, meaning the likelihood of a type 2 error, due to small sample size in 
those particular groups is high, and there may well be a difference that is not detectable at 
that particular power. The same can be said about the URTI clinical diagnosis group, again, 
with a sample size of just 23, is much smaller than the other diagnosis groups, and may be 
too small to detect a statistically significant difference.  
6.2.3 Cytokine analysis 
The main problem encountered with the cytokine analysis was the sample size in each 
group. Due to the very large numbers of samples containing co-infection, finding enough 
samples with one particular pathogen, and one particular pathogen with a particular 
severity for each group was very difficult.  This, along with the heterogeneity of the study 
population, looking at such a variety of severities and clinical conditions, meant that 
comparisons between groups was very difficult, and was probably one of the reasons we 
found such a large level of variation of the results both between and within groups.  
However, as mentioned in section 5.4.1 and 5.4.2 other studies have found conflicting 
results, with some being similar to ours finding no association between cytokine 
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concentrations and severities of disease, and the ones that did find an association were 
ones looking at more specific groups such as a specific severity, age group or clinical 
condition161-163.  
6.3 Conclusions 
In this study population of pre-school children who presented with ARI, we have found very 
high rates of pathogen detection and co-infection compared to previous studies. We also 
found particularly high rates of hBoV, AdV and Mpp infection, none of which have been 
described to the same extent in a similar study population.  
Infection with Mpp or hRSV was associated with more severe disease. No other pathogens, 
co-infection, or inability to detect a pathogen were associated with particular disease 
severities.  
Mpp detection peaked at the end of the rainy season, and was more likely to be associated 
with pneumonia. The high prevalence of Mpp infection has not previously been described 
in this age group, and may have implications for antibiotic use in this particular setting.   
The high rates of pathogen detection may reflect the types of sample collected, the number 
of pathogens tested for, or the population demographic.  
Cytokine profiles were found to be similar with varying severities of hRSV infection and with 
varying pathogens. This may be because the cytokines we investigated are all implicated in 
the broad response to respiratory infection. When taken with the results from previous 
chapters, in which most pathogens were not related with particular clinical manifestations 
or severities, it is not so surprising that particular pathogens did not elicit specific, 
discriminatory responses, just like they did not have specific clinical manifestations. 
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 Differences in concentrations of some cytokines were found when comparing Mpp 
infection to bacteria/virus co-infection. However, samples sizes for all of the cytokine 
experiments were restricted due to the high level of co-infection in the study population, 
and further study is needed to enable more accurate conclusions to be drawn. 
6.4 Further work 
Completing this study has highlighted many avenues of work which could be followed to 
either expand the work that has already been completed, or to develop new studies.  
Although we tested for 17 respiratory pathogens, we did not test for the common bacterial 
pathogens Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenza type b 
(Hib) or the less common Legionella or Bordetella pertussis. S. pneumoniae and Hib were 
discussed in detail earlier, and it would not be feasible to test for these due to the high 
levels of asymptomatic carriage in the nasopharynx. However, it would be possible to test 
for Legionella and Bordetella pertussis, which may add to the results of the study.  
Another area of study which would add to the body of literature on ARI, would be to 
undertake a large study which included control samples.  The only similar study that uses 
control samples is that by van der Zalm et al which was described, along with its limitations, 
in section 6.2.2175. A large prospective study, investigating the prevalence of pathogens in 
samples from children with no respiratory symptoms would be very useful, and may put 
some of our results into context in terms of the likelihood of the particular pathogens being 
causative in each case.  
As previously mentioned, our cytokine work was restricted due to the high level of co-
infection in the study population, meaning sample sizes for each group of single infections 
were small. In order to continue this work, more samples, with more single infections, 
124 
 
would be needed to increase sample size within each group. We also only looked at a 
limited number of cytokines, out of a whole range of known inflammatory mediators. It 
may be that the cytokines we investigated are all implicated in a broad response to 
respiratory infection, and to find a response that discriminates between pathogens, more 
specific mediators may need further investigation. 
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Appendix 1: Reagents 
Chemicals/Reagents Company 
Sample Collection/Processing 
2-mercaptoethanol Sigma-Aldrich, Sao Paulo, Brazil 
Normal Saline 
 0.9% NaCl in H2O 
Baxter, Sao Paulo, Brazil 
RNA lysis buffer Qiagen, Crawley, UK 
RNA Extraction & PCR 
Qiasymphony Mini Kit Pathogen Complex 
200 protocol 
Qiagen, Crawley, UK 
ALT Lysis Buffer Qiagen, Crawley, UK 
Invitrogen Superscript III Platinum One-Step 
Quantitative RT-PCR System 
Invitrogen, Paisley, UK 
Qiagen Quantitect Master Mix Qiagen, Crawley, UK 
Roche Probe Master Mix Roche, West Sussex, UK 
Protein Assay 
QuantiPro BCA Assay Kit: 
 Reagent A 
 Reagent B 
 Reagent C 
Sigma-Aldrich, Dorset, UK 
Bovine Serum Albumin (BSA) Sigma-Aldrich, Dorset, UK 
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Chemicals/Reagents Company 
Phosphate Buffered Saline 
 One sachet was added to 1L distilled 
water. Each litre contained 137mM 
NaCl, 2.7mM KCl, 8.1mM Na2HPO4, 
1.5mM KH2PO4 at pH 7.2-7.4 
Sigma-Aldrich, Dorset, UK 
Cytokine Analysis 
Human Cytokine 8-plex Assay, 1x 96 well: 
 Coupled magnetic beads 
 Pre-mixed, lyophilized standard 
 Standard diluent 
 Detection antibody (10x) 
 Streptavidin-PE (100x) 
 Detection antibody diluents 
 Assay buffer 
 Wash buffer 
Bio-Rad Laboratories Inc., Hemel 
Hempstead, UK 
Bio-Plex Human Cytokine Assay IL-17: 
 Coupled magnetic beads 
 Detection antibody (10x) 
Bio-Rad Laboratories Inc., Hemel 
Hempstead, UK 
Bio-Plex Human Serum Diluent Bio-Rad Laboratories Inc., Hemel 
Hempstead, UK 
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Appendix 2: Equipment 
Equipment Company 
Bio-Plex™ Pro Array 200 System Bio-Rad Laboratories Inc., Hemel 
Hempstead, UK 
Centrifuge – CR3i Multifunction Thermo Scientific, Basingstoke, UK 
Light Cycler 480 RT-PCR System Roche, West Sussex, UK 
Pipettes, single channel: 2-20µl, 20-200µl, 
200-1000µl 
Gilson Inc., WI, USA 
Pipettes, multi-channel: 50-300µl Thermo Scientific, Basingstoke, UK  
Plate Reader ELx800 absorbance microplate 
reader 
BioTek, UK 
Plate Shaker – Titremax 1000 Heidolph, Essex, UK 
QIASymphony Qiagen, Crawley, UK 
Vacuum Manifold Bio-Rad Laboratories Inc., Hemel 
Hempstead, UK 
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Appendix 3: Questionnaire Details 
Demographic Information Clinical Information 
 Housing: 
o Type 
o Size 
o Power supply 
o Water supply 
o Cooking fuel 
o Number of occupants 
o Number sharing a 
bedroom with the child 
o Smokers in the house 
 Age  
 Sex  
 Weight  
 Height  
 Family History: 
o Parent/Guardian’s age 
o Parent/Guardian’s education 
o Parent/Guardian’s 
occupation 
o Number of siblings 
o Household income 
 Birth History: 
o Gestation 
o Birth weight 
 Past medical history: 
o Any previous admissions 
o Allergies 
o Any previous illnesses 
o Any previous respiratory 
symptoms 
 Co-morbidities 
 Vaccinations 
 Breastfeeding 
 Need for admission 
 Discharge date/length of admission 
 Discharge status 
 Presenting signs & symptoms: 
o Coryza 
o Cough 
o Difficulty breathing 
o Wheeze 
o Apnoea 
o Cyanosis 
o Grunting 
o Fever 
o Ear ache 
o Feeding difficulties 
o Lethargy 
o Heart rate 
o Respiratory rate 
o Oxygen saturations 
o Chest indrawing 
o Temperature 
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Appendix 4: PCR Cycling Conditions 
 Temperature (oC) Duration No. of cycles 
Flu, hMPV, hRSV; 
CoV’s; PIV’s, hRV 
50 20 minutes 1 
95 2 minutes 1 
95 10 seconds 50 
58 45 seconds 
72 1 second 
40 30 seconds 1 
AdV, Mpp, Cpp 95 5 minutes 1 
95 10 seconds 50 
95 10 seconds 
58 45 seconds 
72 1 second 
hBoV 95 15 minutes 1 
95 10 seconds 50  
58 45 seconds 
72  1 second 
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Appendix 5: Primer Table 
Assay Oligonucleotide Sequence (5’ to 3’) Concentration 
(µM) 
Citation 
Flu 6-
plex 
hMPV 383 Fwd ACAAAGARGCAAGAAAAACAATGG 0.4 [145] 
hMPV 451 Rev GGTGTGTCTGGTGCTGArGG 0.4  
hMPV 424A (FAM)– 
TCATCAGGyAATATyCCACAAAATC
AGAG –(BHQ1) 
0.2  
hMPV 424B (FAM)– 
TCATCAGGTAACATCCCACAAAAC
CAGAG –(BHQ1) 
0.1  
hRSV Fwd GCAAATATGGAAACATACGTGAAC
A 
0.4  
hRSV Rev GCACCCATATTGTWAGTGATGCA 0.4  
hRSV LC610 (LC610)– 
CTTCACGAAGGCTCCACATACACA
GCWG –(BHQ2) 
0.1  
Flu B Fwd AAATACGGTGGATTAAATAAAAGC
AA 
0.4  
Flu B Rev CCAGCAATAGCTCCGAAGAAA 0.4  
Flu B Cyan 500 (Cyan500)– 
CACCCATATTGGGCAATTTCCTAT
GGC –(BHQ1) 
0.1  
Flu A Fwd AAGACCAATCCTGTCACCTCTGA 0.4  
Flu A Rev CAAAGCGTCTACGCTGCAGTCC 0.4  
Flu A VIC (VIC)– TTTGTGTTCACGCTCACCGT 
–(MGB-NFQ) 
0.1  
H1 Fwd ATTGCCGGTTTCATTGAAGG 0.4  
H1 Rev ATGGCATTYTGTGTGCTYTT 0.4  
Swine H1 LC640 (LC640)– 
ATGAGCAGGGGTCAGGATATGCA
GCCGACC –(BHQ2) 
0.1  
Human H1 
LC670 
(LC670)– 
ATGAGCAAGGATCTGGCTATGCTG
CAGATC –(BHQ2) 
0.1  
PIV 6-
plex 
PIV1 HN525 
Fwd 
GATTTCTGGAGATGTCCCGTAGG 0.4 [145] 
PIV1 HN722 Rev TGACTTCCCTATATCTGCACATCC 0.4  
PIV1 HN556 (FAM)– TACTGAGCAACAACCC –( 
MGB-NFQ) 
0.16  
PIV2 Fwd CCATTTACCTAAGTGATGGAA 0.4  
PIV2 Rev  CGTGGCATAATCTTCTTTT 0.4  
PIV2 LC640 (LC640)– 
AATCGCAAAAGCTGTTCAGTCAC –
(BHQ2) 
0.16  
PIV3 NP300 Fwd CTTTCAGACAAGATGGAACAGTGC 0.4  
PIV3 NP800 Rev AGTTACCAAGCTCTGTTGAGACC 0.4  
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Assay Oligonucleotide Sequence (5’ to 3’) Concentration 
(µM) 
Citation 
PIV NP766 (LC610)– 
CCAATCTGATCCACTGTGTCACCG
CTCA –(BHQ2) 
0.16  
PIV4 NP271 Fwd CAGGCCACATCAATGCAGAATC 0.4  
PIV4 NP407 Rev ATGTCATCCCAGCCAGATCTTG 0.4  
PIV4 NP298 (LC670)– 
ATGATTGCTGCCAGAGCCCCAGAT
GC –(BHQ2) 
0.16  
hRV Fwd TGG ACA GGG TGT GAA GAG C 0.4  
hRV Rev CAA AGT AGT CGG TCC CAT CC 0.4  
hRV HEX (VIC)– TCC TCC GGC CCC TGA 
ATG –(BHQ1) 
0.16  
MS2 F1 TGG CAC TAC CCC TCT CCG TAT 
TCA CG 
0.2  
MS2 R1 GTA CGG GCG ACC CCA CGA TGA 
C 
0.2  
MS2 Cyan 500 (Cyan500)– 
CACATCGATAGATCAAGGTGCCTA
CAAGC–(BHQ1) 
0.08  
CoV 4-
plex 
OC43 Fwd CGATGAGGCTATTCCGACTAGGT 0.4 [146] 
OC43 Rev CCTTCCTAGCCTTCAATATAGTAAC
C 
0.4  
OC43 (Cyan 500) 
TCCGCCTGGCACGGTACTCCCT 
(BHQ1) 
0.16  
NL63 Fwd ACGTACTTCTATTATGAAGCATGAT
ATTAA 
0.4  
NL63 Rev AGCAGATCTAATGTTATACTTAAAA
CTACG 
0.4  
NL63 (FAM) 
ATTGCCAAGGCTCCTAAACGTACA
GGTGTT (BHQ1) 
0.16  
229E Fwd CAGTCAAATGGGCTGATGCA 0.4  
229E Rev AAAGGGCTATAAAGAGAATAAGGT
ATCT 
0.4  
229E (HEX) 
CCCTGACGACCACGTTGTGGTTCA 
(BHQ1) 
0.16  
 HKU1 Fwd TTACTTCCACACTTTTCATCTCTCT
G 
0.4  
 HKU1 Rev CGGAAGCAGCAACGAAATTC 0.4  
 HKU1 (LC640) 
CGCCCACTTGAAGCCGAGACCG 
(BHQ2) 
0.16  
CMA 
3-plex 
Cpp Fwd CAAGGGCTATAAAGGCGTTGCT 0.2 [148] 
 Cpp Rev ATGGTCGCAGACTTTGTTCCA 0.2  
 Cpp (LC670) 
TCCCCTTGCCAACAGACGCTGG 
0.1  
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Assay Oligonucleotide Sequence (5’ to 3’) Concentration 
(µM) 
Citation 
(BHQ2) 
 Mpp Fwd GGAATCCCAATGCACAAGAACA 0.4  
 Mpp Rev GCTTTGGTCAACACATCAACCTT 0.4  
 Mpp (LC610) 
GCCTTGAAGGCTGGGTTTGCGCTA 
(BHQ2) 
0.1  
 Adv Fwd GCCACGGTGGGGTTTCTAAACTT 0.4 [147] 
 Adv Rev GCCCCAGTGGTCTTACATGCACAT
C 
0.4  
 Adv (FAM) 
TGCACCAGACCCGGGCTCAGGTA
CTCCGA (BHQ1) 
0.2  
HBoV 
2-plex 
hBoV NS Fwd CTTGGGCGGGACAGAATGC 0.4  
 hBoV NS Rev AACAGAATTGCCACCAACAACC 0.4  
 hBoV NS (FAM) TCAAGCATAGAGACAGT 
(MGB) 
0.2  
 hBoV NP Fwd GCTCGGGCTCATATCATCAGG 0.4  
 hBoV NP Rev CTCCCTCGTCTTCATCACTTGG 0.4  
 hBoV NP  (VIC) AATCAGCCACCTATC (MGB) 0.2  
 
